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Roadmap for Metal Nanoparticles in Radiation 
Therapy: Current Status, Translational 
Challenges, and Future Directions. 
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Abstract: 
This roadmap outlines the potential roles of metallic nanoparticles (MNPs) in the field of radiation 
therapy. MNPs made up of a wide range of materials (from Titanium, Z=22, to Bismuth, Z=83) and a 
similarly wide spectrum of potential clinical applications, including diagnostic, therapeutic (radiation 
dose enhancers, hyperthermia inducers, drug delivery vehicles, vaccine adjuvants, photosensitizers, 
enhancers of immunotherapy) and theranostic (combining both diagnostic and therapeutic), are being 
fabricated and evaluated. This roadmap covers contributions from experts in these topics summarizing 
their view of the current status and challenges, as well as expected advancements in technology to 
address these challenges. 
 
Contents: 
List of contributions: 
Overview of metal nanoparticles for Imaging and Therapy 
1. Gold Nanoparticles for Imaging and Therapy - James F. Hainfeld 
2. Magnetic Nanoparticles for MRI and Radiotherapy – Hilary Byrne, Yaser Gholami and Zdenka 
Kuncic 
3. Gadolinium Nanoparticles for Imaging and Therapy in Oncology - François Lux, Ross Berbeco, 
Olivier Tillement 
4. Iodine Nanoparticles – James F. Hainfeld, Sharif M. Ridwan, Yaroslav Stanishevskiy, Henry M. 
Smilowitz 
MNP Imaging  
5. Optical and Photoacoustic Imaging of GNPs - Dmitry Nevozhay and Konstantin V. Sokolov 
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Figure 1: Graphic illustration of how each contribution in this collection connects to the study of (metallic) nanoparticles and 
their interaction with cells and radiation. 
Introduction: 
MNPs are characterized by their small size (typically <100nm), large surface area to volume ratio, and 
high interaction cross-section with incident ionizing or non-ionizing radiation. The high radiation 
interaction cross-section is well known but modeling, mechanistic underpinning, and extensive 
characterization of consequences of physical, chemical and biological interplay in mediating anti-tumor 
effects remains inadequately understood. A variety of MNPs are also quite readily endowed with 
biological functionalities such as stealth coatings that help them evade capture and clearance by 
circulating and tissue-resident macrophages. MNPs can further be decorated with tumor targeting 
ligands that facilitate tumor homing or coupled with photosensitizers or other biological mediators of 
tissue damage.  To penetrate fortified stromal barriers erected by tumors including vasculature, 
fibrous/connective tissue, and immune evasion strategies, MNPs can further be armed with multiple 
ligands specific for each barrier. Not surprisingly, this interface between nanomaterial design, radiation 
interaction, and tumor biology is a fertile ground for active research by multiple disciplines, often with 
non-intersecting boundaries.  
This special issue roadmap is an attempt to collate and weave together the extant knowledge in the 
arena of nanoparticle research. By including experts from diagnostic, therapeutic and theranostic 
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applications of MNPs, we endeavor to provide a broad overview in the field, benchmarking what is 
known today, which gaps in knowledge and technology will be addressed in the near future and 
forecasting what the future horizons hold in store.  
Page 5 of 128 AUTHOR SUBMITTED MANUSCRIPT - PMB-109530.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
us
cri
pt
Gold Nanoparticles for Imaging and Therapy 
James F. Hainfeld 
Nanoprobes, Yaphank, NY, USA 
 
Status 
 Imaging: The extensive historical wealth of chemistry of gold nanoparticles (GNPs) with their 
high density, high atomic number, variable size, and facile attachment of a variety of ligands make them 
ideal as imaging agents.  Once passivated to be biologically tolerated, they can be injected intravenously 
or locally, or embedded in other materials and devices.  Imaging can be by X-ray absorption (e.g., CT or 
microCT), but newer devices rely on X-ray fluorescence(Manohar et al 2016); gold can also be 
radioactive.  The nanoparticle aspect gives them more flexibility and control by adjusting size, shape, 
and adding one or more targeting ligands(Panahi et al 2017).  This allows control over blood half-life, 
clearance, and specific uptake.  Results are showing excellent vasculature imaging as well as tumor 
imaging(Hainfeld et al 2006) and other targets such as stroke clots(Kim et al 2017).  Cells (e.g., 
macrophages) have been loaded with GNPs and shown to target vulnerable plaque(Chhour et al 2016).  
Gold nanoparticles have been the favorite choice for electron microscope studies for cell and molecular 
labeling (e.g., with immunogold).  GNPs have been combined with fluorescent molecules to provide dual 
labeling(Takizawa and Robinson 2003).  Some GNPs are fluorescent.  GNPs are also useful for 
photoacoustic imaging and as SERS probes.   Silver and gold enhancement, which catalytically deposits 
silver or gold on the GNPs grows their size to a level detectable by the light microscope for histology or 
other studies(Hayat 1995).  This metallic growth also increases the sensitivity.  Larger GNPs (~30nm) can 
be seen in low (pM) concentration by the naked eye and are commonly used in lateral flow devices, such 
as the pregnancy test kit, or strips to detect infectious diseases. In short, GNPs have been and are a 
tremendously useful platform for imaging. 
 Therapy: One group showed cells grown on a gold monolayer were killed 160 times more than 
those grown on plastic after X-ray irradiation(Regulla et al 1998).  X-rays are absorbed by gold atoms, 
knocking out electrons that create ionizations and free radicals, so more dose is deposited locally 
around the gold.  It was shown that gold nanoparticles delivered to tumors (in test animals) and 
irradiated resulted in much greater tumor destruction than radiation alone(Hainfeld et al 2004).  A 
number of groups have contributed extensive theoretical modeling to better understand and predict 
these effects10(Her et al 2017).  Gold better absorbs kV energy X-rays (<400 keV) than MV (>4 MV) X-rays 
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so the photoelectric effect and radioenhancement have generally been shown to be best in the kV 
range(Butterworth et al 2012).  However, since clinical irradiations are done with LINACS in the MV 
range, some studies focused on that range and have also shown significant dose enhancement.  GNPs 
also enhance proton therapy. 
Gold nanoshells and nanorods absorb near infrared radiation (NIR, ~800 nm) enabling heating of 
tumors or lesions and their subsequent ablation (photothermal therapy) (Ahmad et al 2016).  NIR is 
reduced by a factor of 10 in 2 cm of tissue which limits this to superficial lesions.  However, a clinical trial 
is underway using an array of light pipes to irradiate and heat deeper prostate cancers (clinicaltrials.gov 
ID NCT02680535). 
 
 Current and future challenges  
 For ex-vivo or animal imaging at the macroscopic, light, and electron microscope levels, new 
targeting moieties and reactive groups will further add functionality and enable new applications.  The 
challenge will be to synthesize these functionalized nanoparticles and yet retain appropriate stability.  
For example, putting a novel targeting moiety on the GNP surface may induce unwanted aggregation. 
 In vivo imaging and therapy with GNPs has been achieved for small animals.  However, 
translation to human use has lagged and largely not been done due to several problems: 1) poor 
clearance, 2) skin discoloration at high levels, 3) possibly high cost (although reasonable if benefit is 
great).  CT imaging has high resolution but low sensitivity so relatively large amounts of GNPs need to be 
injected, raising the issue of toxicity.  For therapy, only a small amount of what is injected iv ends up in 
the tumor, again requiring relatively large amounts to be injected.  Local injections mostly avoid this 
problem but do not adequately address most clinical cases where there are multiple lesions, some 
microscopic, and a direct injection may not fully cover all cells, leaving some undertreated with resulting 
recurrence(Smilowitz et al 2018).  Clearance is also a problem.  Less than 5 nm particles can exit rapidly 
via the kidneys.  However, this fast clearance does not give enough time to maximally load tumors or 
other targets.  IV antibodies take ~24 hours and multi-passes to maximally load targets.  These particles 
then clear via the hepatobiliary route, but unfortunately, macrophages take up the GNPs throughout the 
body and because gold is insoluble and not digestible it just stays in cells.  Liver clearance has been 
reported to be only 9% in 6 months(Sadauskas et al 2009).  This whole body retention will be a problem 
for FDA approval.  Because GNPs are highly colored, cells in the skin (probably mostly macrophages) 
take them up and skin discoloration is virtually permanent.  Gold is also costly.  Unless small amounts 
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can be utilized for in vivo purposes, these factors present significant challenges and have impeded 
progress toward the clinical translation of GNPs(Cui et al 2017, Schuemann et al 2016). 
 Additionally, as mentioned, GNP X-ray dose enhancement is better with kV photons than 
megavoltage, but MV instruments are the ones currently used clinically due to better penetration to 
deep tumors. 
 
Advances in science and technology to meet challenges 
 For tumor and other targeted imaging and therapy of GNPs in humans, one solution is to use 
small acceptable amounts of gold.  Imaging using fluorescent photons is more sensitive than CT, and 
development of this equipment is underway.  Heating of superficial or deeper tissue with light pipes and 
NIR appears to work well with small amounts of gold nanorods or nanoshells injected iv.  For better 
clearance <6 nm particles in a biodegradable matrix have been developed to extend blood half-life, then 
later break down and be cleared through the kidneys.  However, during the long blood residence they 
will be taken up by macrophages and may have difficulty exiting the lysosomes, even when the polymer 
is digested.  Because of the ease of chemically functionalizing GNPs with thiols that bind to their surface 
the problems of passivating them to avoid toxicity and linking targeting molecules (e.g., peptides and 
antibodies) does not appear to be a problem for GNPs as it can be for other types of NPs.  The amount 
of gold needed for X-ray dose enhancement (at kV) is calculated to be rather high (~2% Au by weight) 
for a significant effect.  However, some experiments have shown good dose enhancement with far less 
gold and using MV photons(Wolfe et al 2015).  Usually a poorly understood biological effect is invoked 
to explain such unexpected results, but indicates that some GNPs might be acceptable for clinical use.  
Other high atomic number nanoparticles (e.g., Gd, Ho, Ti, I) may provide favorable alternatives. 
 Concerning the kV vs. MV controversy, kV methods are being revisited: 1) Grid, microbeam, and 
minibeams.  Spatially segmented beams (intervening non irradiated zones) were found to eliminate the 
high skin entrance dose of kV X-rays(Dilmanian et al 2019); 2) Stereotactic kV irradiation also avoids 
entrance dose; 3) CT machines use bow-tie filters that upon rotation produce isodose in the subject, 
again avoiding skin entrance dose and dose fall-off(Schultz et al 2011).  kV machines are much less 
expensive, portable, and require less shielding, and could make nanoparticle dose enhancement cancer 
treatments available to developing countries. 
   
Concluding remarks 
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 GNPs have incredibly useful properties and flexibility making them one of the best choices for 
imaging all the way from EM to animal imaging, using various methods including electrons, ultrasound, 
protons and X-rays.  For therapy a number of forms have been developed for heating, drug release, and 
dose enhancement.   
 I have been making and using GNPs for over 40 years. A focus has been their dose enhancement 
for improved cancer therapy. They are among the best radioenhancers ever found.  However, the 
problems with clinical translation have driven me to develop iodine nanoparticles that have better 
clearance, are colorless (no skin discoloration) and are less expensive(Hainfeld et al 2019, 2018). It is 
hoped that these, GNPs, or other dose enhancing NPs will soon be useful for patients. 
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Status 
In addition to demonstrating therapeutic gain with nanoparticle-enhanced radiotherapy, it is also 
advantageous to incorporate imaging to aid in diagnosis, monitor treatment response or to track 
nanoparticle uptake. Many options exist for leveraging existing diagnostic procedures (CT contrast, 
magnetic resonance imaging (MRI) contrast, positron emission tomography (PET) tracers).  MRI stands 
out due to providing soft tissue contrast and use of non-ionizing radiation. Nanoparticles enhancing 
MRI contrast can therefore show detailed organ-specific uptake and can exploit differential tissue 
uptake in disease diagnosis without exposing patients to extra dose.  
Current clinically-used MRI contrast agents contain gadolinium (Gd) which, with seven unpaired 
electrons, confers strong longitudinal (T1) contrast. Chelated Gd nano-structures can provide 
diagnostic-quality MRI contrast. However, MRI contrast can also be achieved with Fe3+, Fe2+, Mn2+ 
and super-paramagnetic iron oxide nanoparticles (SPIONs). 
SPIONs are well known for their MRI contrast-enhancing capability, due primarily to their ability 
to shorten the transverse (T2) relaxation time of water protons (Weinstein et al. 2010). The current 
status of SPION-enhanced contrast MRI is evolving rapidly as concern grows over long-term toxicity of 
conventional Gd-based contrast agents (Fornell 2018).  
In radiotherapy, enhancement by SPIONs has been investigated in simulation studies (McMahon 
et al. 2016) and demonstrated in vivo using synchrotron x-rays (Choi et al. 2012) and proton beams  
(Kim et al. 2012). Remarkably, none of these studies explored the potential to leverage the MRI 
contrast-enhancing properties of SPIONs alongside their radio-enhancement properties. Such studies 
are needed, given the increasing role of MRI in treatment planning and the urgent need for high-
precision measurement of the Bragg peak in particle therapy.  
 
Current and future challenges 
In addition to addressing the challenges in clinical translation, a novel nanotheranostic for 
radiotherapy enhancement must be forward-looking, taking advantage of and enhancing emerging 
technologies. The combination of imaging with therapy is an overarching theme of these emerging 
techniques, with utilisation of MRI in particular expected to increase in future. Many nanoparticles for 
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radio-enhancement are currently under development or have been reported on over the last 20 years, 
but none have yet been successfully translated for clinical use (Kuncic and Lacombe 2018; Schuemann 
et al. 2016).  
Three recent innovations invite the development of magnetic nanoparticles for MRI and 
radiotherapy which can rise to this challenge: 
1. The MRI-linac  
MRI-linac technology enables image-guided radiotherapy with precise targeting of soft-tissue 
structures (Liney et al. 2018). Best practice implementation and workflows exploiting the advantages 
of time-of-treatment MR imaging are still being explored (Liney et al. 2019). This provides an 
opportunity for magnetic nanoparticle enhancement to be incorporated as part of standardised 
treatment as that is developed. Along with visualisation of anatomical changes during treatment, the 
MRI-linac offers the tantalizing prospect of observing the effects and perhaps effectiveness of 
radiation treatment inter- and intra-fraction. This poses a challenge for nanoparticle treatments to 
become adaptive, identifying and responding to individual patient response during a course of 
treatment.   
2. Particle therapy 
In particle therapy, a key current challenge to be met is integration of image-guidance techniques, 
similar to that successfully used in conventional MV-beam radiotherapy. MRI offers arguably the best 
option, especially with pencil beam scanning, where a relatively straightforward technique can be 
applied to correctly locate the Bragg peak for each pencil beam (Oborn et al. 2017). A future challenge 
is leveraging SPIONs for enhancing both MRI contrast and radiotherapeutic efficacy in particle therapy 
(Liu et al. 2018). Feasibility studies are required to explore the potential of this concept.   
3. Targeted internal radiotherapy 
To date, the effects of radio-enhancement in many in vivo, in vitro and in silico studies have mainly 
been considered in the context of radiation delivered by an external beam (i.e. external beam 
radiotherapy or brachytherapy) (Schuemann et al. 2016). Targeted internal radionuclide therapy is an 
alternative treatment approach to achieve more localized radiotherapy by delivering short range 
radiation via internalization of radioisotope in a tumour (Zhang et al. 2010). Leveraging an appropriate 
nanoparticle delivery vehicle gives access to MRI-based tracking and diagnostics (Gholami et al. 2015).  
 
Advances in science and technology to meet challenges 
1. Gd-based nanoparticles for MRI-linac application 
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Radio-enhancing nanoparticles with inbuilt MRI contrast are well within current capabilities, and 
perfectly suited to take advantage of the recent development of MRI-linacs. Utilising conventional Gd 
contrast, the AGuIX® nanoparticle has been designed for radio-enhancement and MRI contrast. This 
nanotheranostic has undergone extensive pre-clinical evaluation and has progressed to phase I clinical 
trial using conventional separate MRI and radiotherapy treatment (Verry et al. 2019). Its applicability 
to combined MRI-linac systems is obvious, where time-of-treatment imaging gives information on 
nanoparticle uptake at each treatment fraction. 
2. SPIONs for MRI-guided particle therapy 
To demonstrate the feasibility of SPION radio-enhancement in particle therapy, advances are needed 
in both simulation and experimental approaches. In simulations, more studies are required to advance 
our knowledge of the physico-chemical stage of radiation damage and to correctly quantify the radio-
chemistry processes in the immediate vicinity of activated SPIONs  (Rudek et al. 2019). Technological 
advances are also needed in both software and hardware to enable MRI-guidance in particle therapy 
(Oborn et al. 2017), which will allow new experiments to be designed to evaluate radiotherapeutic 
gain by SPIONs.   
3. Radio-labelled SPIONs for targeted internal radiotherapy and PET/MRI 
Nanoparticles can be labelled with various radioisotopes for use in both internal radionuclide therapy 
and diagnostic imaging (Boros et al. 2015; Yuan et al. 2018). SPIONs are the best candidates for a 
radiolabelled nano-theranostic platform (Figure 1) due to their favourable physical and chemical 
properties for chelate-free radiolabelling (Yuan et al. 2018), their MRI contrast properties, and their 
excellent biocompatibility (Iv et al. 2015). 
The six main types of radiation clinically used for internal radionuclide therapy and emission 
tomography are: !", !#, $ particles, Auger electrons, conversion electrons, and %-rays (Ersahin et al. 
2011). As the energy of the emitted particles is typically in the kilo-electronvolt (keV) range for Auger 
electrons, !", !#particles, the probability of interaction with high-Z nanoparticles can be significantly 
higher than that for an external photon beam, which is typically in the mega-electronvolt (MeV) 
energy range. The interaction probability is also increased by the close proximity of the radiation 
source to the nanoparticles. Thus, radio-enhancement by nanoparticles should be more significant for 
internal radionuclide therapy than for external beam radiotherapy (Gholami et al. 2019).  
In addition, theranostic radioisotopes such as 67,64Cu (!", !#, %), 90Y (!", !#) and 177Lu (!", %) 
decay with multiple radiation species enabling them to deliver simultaneous in vivo dose 
quantification by utilizing nuclear imaging (e.g. PET).  
The inherent MRI contrast afforded by radio-labelled SPIONs in addition to PET imaging and 
delivery of a therapeutic radiation dose delivers a compelling theranostic platform.  
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Figure 1. Schematic diagram of a radiolabelled SPION platform for internal radiotherapy and 
multimodal imaging. 
 
Concluding remarks 
Radiotherapy enhancement can be achieved with nanoparticles incorporating MRI contrast, exploiting 
some of the latest and most exciting innovations in the radiotherapy space: MRI-linacs; image-guided 
particle therapy; and radionuclide theranostics. SPION-enhanced MRI-guided particle therapy, in 
particular, presents an exciting concept that integrates several advanced technologies that up until 
now have been studied disparately. Feasibility studies are needed to demonstrate the potential 
benefits of this new paradigm. 
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Gadolinium as molecular agent.  
Gadolinium is the most frequently used lanthanide in the clinic essentially as positive contrast agent 
for magnetic resonance imaging (MRI) since the 80s.  A molecular agent (Motexafin gadolinium) has 
been used in combination with radiotherapy for treatment of glioma, non-small cell lung cancer and 
brain metastases.1 Despite good tolerance of the treatment and encouraging preclinical results, 
motexafin gadolinium did not succeed in increasing significantly overall survival. 
Metal based nanoparticles for radiotherapy.  
Most of the studies performed on radiosensitization used nanoparticles taking advantage of gathering 
high Z elements in a single object. The potential of this strategy for enhancing the efficacy of 
radiotherapy has been shown even at very small concentrations of NPs in tumors (ppm range) 
associated with enhancement factors varying from 10 to 100% using different elements.2,3 McMahon 
et al. have proposed a nanoscale dose deposition mechanism that leads to important formation of 
radical species in direct vicinity of the nanoparticles.4 Despite intense research, only two nanoparticles 
have been accepted for clinical trials as radiosensitizers for the moment: (i) NBTXR3 (hafnium oxide 
NPs) administered locally5 and AGuIX (polysiloxane based NPs surrounded by gadolinium chelates) 
administered intravenously.6 
Why develop ultrasmall nanoparticles for radiosensitization ?  
Development of ultrasmall NPs with a hydrodynamic diameters of less than 5 nm for biomedical 
applications is relatively recent due to different reasons: (i) NPs have been initially developed for drug 
delivery needing large cargo for chemotherapeutic agents, (ii) the enhanced permeability and 
retention effect was described to be limited to larger NPs (HD > 10 nm; mass > 40 kDa)7 and is limited 
to uptake around 1% of the administered dose,8 (iii) larger NPs are characterized by higher interaction 
with X-Rays and (iv) display longer circulation time in the bloodstream, (v) difficulties to gather imaging 
and therapeutic functionalities in smallest nano-objects.  
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However, advantages of ultrasmall hybrid nanoparticles over regular nanoparticles may be key points 
for their further rapid translation into the clinic: (i) large nanoparticles are often severely accumulated 
in organs like liver and spleen9 while ultrasmall NPs are rapidly eliminated by the kidneys after 
intravenous administration,10 (ii) prolonged accumulation in organs for large nanoparticles can be 
associated with toxicity due to presence of metals, (iii) smaller nanoparticles are associated with 
better penetration in tumors,11 (iv) the size of NPs has also tremendous impact on interaction with X-
Rays, indeed for larger nanoparticles most of ionizing events like secondary electrons occur in the bulk 
of the NPs drastically reducing deposited dose around the NPs.12 
Why use gadolinium-based nanoparticles for image guided radiotherapy? 
Our team has shown gadolinium to be of interest for radiosensitization by developing AGuIX NPs. 
These NPs act as an efficient radiosensitizer under different types of irradiations (photons from keV 
to MeV, protons or carbons), are efficiently uptaken in tumors by the EPR effect after intravenous 
administration in animals or in patients with retention for more than a week (particularly adapted for 
fractionated radiotherapy) and are eliminated effectively by the renal clearance.8 Gadolinium is a 
choice element for its MRI contrast agent properties to better delineate the tumor before 
radiotherapy which is a key factor for modern radiotherapy. Indeed, the new generation of 
radiotherapeutic techniques has led to the possibility to deliver very precisely increased dose in the 
tumor.13 In these conditions, the delivery of the dose is challenging due to uncertainties of imaging, 
requiring precise delineation of tumors to avoid unwanted irradiation of surrounding tissues especially 
for tumors located close to organs at risk. The use of MRI is increasing considerably for radiotherapy 
planning due to its excellent contrast in soft tissues in comparison with CT (computed tomography) 
and the absence of ionizing radiation especially for pediatric cancer.14  
In this perspective, the development of MRI/LINAC is a real opportunity that synergizes very well with 
gadolinium based compounds. Two apparatus are now on the market and display magnetic fields of 
0.35 T (ViewRay) and 1.5 T (Elekta),15 which are relatively low in comparison to new MRI apparatus 
resulting in lower signal-to-noise ratios and resolution. These apparatus will highly benefit from 
positive contrast agents, especially nanoparticles like AGuIX that present two to three times higher 
longitudinal relaxivities in comparison to commercial molecular agents. In our opinion, the association 
of MRI-LINAC with gadolinium based nanoparticles creates synergies and can become the new 
standard of care for different cancer indications needing better targeting. 
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Iodine Nanoparticles 
James F. Hainfeld1*, Sharif M. Ridwan2, Yaroslav Stanishevskiy1, Henry M. Smilowitz2 
1 Nanoprobes, Yaphank, NY, USA 
2 University of Connecticut Health Center, Farmington, CT 
 
Status 
 Radiotherapy (RT) is used in about 70% of all cancer treatments.  High atomic number (Z) 
radiosensitization is an intriguing strategy for improving RT effectiveness and could therefore benefit 
many patients.  Tremendous efforts have explored and advanced implementation, including theoretical 
analyses, chemical syntheses of novel high-Z nanoparticles, in vitro and in vivo experimental studies, 
even some with patients.  However, progression to routine clinical success is still yet to be achieved. 
 
Current and Future Challenges 
For optimal use the requirements should include: 1) use of kV X-rays (Cho, 2005, Pignol and 
Lechtman, 2012,), 2) low toxicity, 3) achieving >0.5% of the heavy atom concentration (by weight) in the 
tumor (Loughery et al., 2019), and 4) use of IV rather than intratumoral injection (Smilowitz et al., 2018).  
However, not meeting some of these requirements may still result in some patient benefit.  Highly 
loading tumors by IV delivery (requirements 2&3) is challenging since only a fraction of the injected dose 
will home to the tumor, even with targeting.  This means that the material must be non-toxic at very 
high levels (grams/kg administration), a failure of most nanoparticles. Also, maximal IV tumor loading 
takes many circulatory passes and typically takes at least a day. The nanoparticle must therefore be 
larger than the kidney filter (~5nm) and have a long blood half-life, also avoiding rapid liver/spleen 
depletion.  Very few nanoparticles have met these requirements.  For example, gold nanoparticles 
satisfy many of the above mentioned requirements, but have very poor whole body clearance (<10% 
liver clearance in 6 months, Sadauskas et al., 2009) and permanently discolor the skin at the high levels 
needed (Hainfeld et al., 2018). 
 
Advances in Science and Technology to meet the Challenges 
 Iodine is a candidate heavy element and the successful development of non-toxic X-ray contrast 
media has led to radiosensitization clinical trials, originally by Norman and collaborators (Rose et al., 
1999) using a modified CT, and later by Adam and collaborators (Adam et al., 2016) using a synchrotron 
(tumor concentration reaching 0.3%). A deficiency with this approach is the rapid kidney clearance 
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which compromises tumor loading and tumor to non-tumor ratios. Our solution was the synthesis of 
iodine nanoparticles (INPs, Hainfeld et al. 2018) which are non-toxic at 7 g iodine/kg, 20 nm in size, and 
show a blood half-life of 40 hours (2.7 days). The INPs (Fig. 1) are colorless and do not discolor skin and 
show slow but steady whole body clearance (>90% over 15 months). These INPs were found to 
specifically load orthotopic glioma brain tumors in mice to 0.6% and showed a doubling or more median 
life extension after kV irradiation compared to irradiation without the INPs. Improvements may be 
expected with active targeting and treatment of brain metastases where we have observed much higher 
levels of INP loading. We also found that INP-enhanced RT of advanced othotopic human gliomas in 
mice synergizes with DOXIL chemotherapy (Hainfeld et al., 2019, Fig. 1e) raising the possibility that INP-
RT may benefit other combination therapies including chemo-, immune- and oncolytic virus therapies.   
 
Concluding Remarks 
Iodine nanoparticles therefore appear to overcome problems with many other high atomic 
number nanoparticles and should help advance high-Z nanoparticle radiosensitization to clinical use and 
patient benefit. 
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Figure 1.  Iodine nanoparticles: (a): Electron micrograph; (b):schematic; (c): accumulation in U87 glioma 
in mouse (microCT), (d): therapeutic efficacy, and e) INP-RT greatly increases Doxil effectiveness.  Taken 
from Hainfeld et al., 2018, 2019. 
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Optical and Photoacoustic Imaging of GNPs 
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Status 
The use of GNPs in biomedical optical and photoacoustic imaging was facilitated by few key 
properties. First, gold has been known to be non-toxic and biocompatible since antiquity. Second, 
current methods allow production of GNPs in various sizes and shapes which enables tuning of their 
physico-chemical properties. Third, GNPs exhibit strong surface plasmon resonances in visible and 
near-infrared (NIR) regions that are ideally suited for imaging of biological specimen. Lastly, the 
surface of GNPs can be easily modified to introduce various functionalizations  including targeting 
moieties  or different coatings that can alter biological interactions.  
We reported one of the first studies demonstrating optical imaging using GNPs conjugated with 
anti-EGFR antibodies for specific labeling of cancer cells in cultures and biopsies from cancer patients 
(Sokolov et al., 2003). This approach is based on the ability of GNPs to strongly scatter light due to 
excitation of surface plasmon resonances, which are dependent on size and shape of GNPs, and also 
physical proximity between  the individual particles . We showed that molecular specific interactions 
of immunotargeted GNPs with cells can lead to formation of closely spaced GNP assemblies that are 
associated with a strong red shift in GNPs scattering spectra due to the plasmon resonance coupling 
(Sokolov et al., 2003, Aaron et al., 2009). This phenomenon was used for optical imaging of cancer 
cells with high contrast in cell cultures, tissue phantoms and animal models (Aaron et al., 2007, Aaron 
et al., 2009).  A number of elegant studies used the effect of plasmon resonance coupling to image 
interactions and trafficking of biological molecules with sub-diffractional spatial resolution including 
dynamic behavior of integrin molecules on a cellular cytoplasmic membrane (Rong et al., 2008), 
transport of cell membrane receptors to endosomes (Aaron et al., 2009), and monitoring of caspase-
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3 activity in live cells (Jun et al., 2009). In parallel with the imaging studies, a theoretical framework 
was introduced to estimate distances between coupled gold nanoparticles that provided the 
foundation for the concepts of “plasmonic ruler” and “plasmon coupling microscopy” (Wu and 
Reinhard, 2014) as new tools in biological imaging.  
GNPs also exhibit a strong two-photon luminescence (TPL) providing another dimension in 
biological applications that was first demonstrated in imaging of a single gold nanorod (GNR) in a 
mouse ear blood flow (Wang et al., 2005). Subsequently, TPL with GNPs was applied for molecular 
imaging of cancer cells (Durr et al., 2007). GNPs with NIR extinction spectra are ideally suited for TPL 
imaging in vivo due to increased tissue penetration in the NIR . Further, GNPs exhibit a very short, in 
order of tens of picoseconds, fluorescence lifetime under two-photon excitation as compared to 
nanoseconds for organic fluorophores that can enable high contrast in fluorescence lifetime imaging 
microscopy (FLIM) of cells and tissue (Zhang et al., 2010).  
The absorbance property of GNPs was used to enable sensitive molecular imaging in optical 
coherence tomography (OCT) (Lapierre-Landry et al., 2017). In this method a modulated heating laser 
is used to induce highly localized oscillating changes in the refractive index of media in immediate 
vicinity of a GNP. These oscillations are detected with high sensitivity by OCT and allow detection of 
GNPs with high contrast (Lapierre-Landry et al., 2017).    
Introduction of photoacoustics (PA), a hybrid modality with optical excitation and ultrasound 
detection, provided an imaging depth of several centimeters in tissue . PA signal is generated by a 
thermoelastic expansion of media around light-absorbing molecules or nanoparticles. GNPs found 
their application in PA imaging (PAI) due to their exceptionally high absorbance that is several orders 
of magnitude higher than that of organic dyes. Initial studies demonstrated the use of gold nanoshells 
coated with polyethylene glycol (PEG) for visualization of the vasculature in a rat brain (Wang et al., 
2004). Subsequently, we showed that plasmon resonance coupling can also be used in PA for highly 
sensitive detection of labeled cancer cells using antibody targeted GNPs (Mallidi et al., 2007). Later, 
we used plasmon resonance coupling to achieve an unprecedented sensitivity of just few tens of 
cancer cells in lymph node micrometastases in animal models of head and neck cancer (Luke et al., 
2014). PAI with GNPs also showed significant promise in cell tracking applications including 
mesenchymal stem cells (Donnelly et al., 2018). Further, GNPs were used in multimodal strategies for 
tumor detection using PAI and margin delineation by  Surface-Enhanced Raman Scattering (SERS) 
(Kircher et al., 2012). 
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Current and future challenges 
Most of NIR absorbing GNPs showed unfavorable pharmakokinetics (PK) with a low accumulation 
at a target site, e.g. tumor, following i.v. administration. This behavior could be associated with a 
relatively big size, typically >60 nm, and instability of GNP coating in blood.  
Generally, particles with size <5 nm are quickly excreted via kidneys, usually within several hours , 
whereas an increase in size is associated with a higher propensity of uptake by the reticuloendothelial 
system (RES) and an increased accumulation in liver and spleen where GNPs can reside for months 
while slowly being excreted via the hepatobiliary route (Poon et al., 2019).  
Coating of GNPs with PEG or other biocompatible polymers is the most common approach to reduce 
opsonization and subsequent uptake of GNPs by RES. The efficiency of this protection is dependent 
on the density of PEG molecules on the GNP surface . However, PEGylation does not eliminate non-
specific uptake by RES  as polymer molecules can be displaced by physiological concentrations of 
cysteine and cystine (Larson et al., 2012).  
High levels of accumulations and a long residence time of NIR-absorbing GNPs in liver and spleen in 
combination with non-biodegradable nature of gold brings up concerns about potential long term-
toxicity. Most studies report no significant adverse effects of GNPs ranging in size from 12 to 85 nm . 
Comprehensive evaluations that take into account the whole nanoparticle construct including the 
coating and the geometry (e.g., size and shape) of the gold core most likely will be required for each 
GNP that is considered for a clinical translation.  
Another common problem of NIR-absorbing GNPs is their decreased photostability due to thermal 
degradation caused by laser irradiation with a high peak intensity that leads to a decrease of the 
photoacoustic signal (Chen et al., 2010).  
Advances in science and technology to meet challenges 
The thermal instability of GNPs can be addressed by a combination of advanced GNP synthesis and 
surface modification techniques. Specific examples include silica coating of GNRs (Chen et al., 2010) 
as well as synthesis of miniature GNRs (Chen et al., 2019).  
To address challenges of clinical translation of GNPs, we introduced the concept of biodegradable 
plasmonic nanoparticles that consist of 5 nm GNPs assembled into sub-100 nm nanoclusters using 
biodegradable polymers (Tam et al., 2010). In a biological media the nanoclusters can fully dissociate 
over time into primary 5 nm particles which are favorable for a rapid clearance form the body. 
Delivery of GNPs to tumor can be improved by developing better coatings. We showed that 
inclusion of a small alkyl chain between the gold surface and the outer PEG layer can greatly improve 
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stability of GNPs and diminish their uptake by macrophages up to 5 days (Larson et al., 2012). Another 
approach is based on the use of erythrocyte membranes as a GNP coating that was shown to decrease 
GNP uptake by macrophages (Gao et al., 2013).  
Concluding remarks 
Intricate dependence of plasmon resonances of GNPs on their geometry, interparticle distance and 
environment has led to innovative directions in development of biosensors, bioanalytical assays and 
cell imaging tools. There is also continuous flow of exciting reports of preclinical imaging and 
therapeutic developments involving GNPs. Future adoption of GNPs in the clinic will rely on 
optimization of GNPs pharmacokinetics in vivo and a better mechanistic understanding of GNPs 
toxicity and clearance. Applications of GNPs for intravital imaging, cell tracking , and therapy  will likely 
undergo further exploration with emphasis on multimodal imaging and theranostic approaches.  
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Status 
Over the last decade, x-ray fluorescence (XRF) computed tomography (XFCT), traditionally a 
synchrotron x-ray imaging modality, has also been implemented with ordinary polychromatic x-
ray sources (viz., “benchtop XFCT”), aiming to enable routine XFCT imaging of biological objects 
(e.g., small animals) under typical biomedical laboratory settings. In particular, it was the absence 
of a proper quantitative imaging tool for small animal studies involving high atomic number (Z > 
50) metallic nanoparticles, such as gold nanoparticles (GNPs), which prompted the initial efforts 
on benchtop XFCT development with small animal-sized phantoms (Cheong et al., 2010; Jones 
et al., 2012). The feasibility of extending benchtop XFCT beyond GNP imaging has been 
demonstrated through similar phantom imaging studies using high-Z probes such as platinum, 
gadolinium and iodine (within the context of multiplexed imaging) (Kuang et al., 2013a; Kuang et 
al., 2013b), as well as low-Z molybdenum NPs (Hertz et al., 2014).  
 
To date, a clear pathway towards the fulfillment of the aforementioned goal of benchtop XFCT 
imaging has been well established, for example by the first successful animal imaging study 
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(albeit performed postmortem) using an experimental benchtop XFCT system and GNPs 
(Manohar et al., 2016). More recently, another postmortem animal imaging study has 
demonstrated the feasibility of benchtop XFCT imaging of mice injected with molybdenum NPs 
(Larsson et al., 2018). Additionally, very recent publications have reported benchtop XFCT and 
XRF imaging/mapping of live mice injected with gadolinium NPs (Zhang et al., 2019) and GNPs 
(Jung et al., 2020), respectively. Despite these reports and other on-going (unpublished) efforts, 
in vivo imaging with benchtop XFCT is still in its infancy. In particular, the feasibility of performing 
whole-body imaging of live animals using benchtop XFCT techniques, while meeting the key 
requirements for routine applications (to be described below), has yet to be demonstrated.  
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Figure 1. Illustration of the possibility of quantitative multimodal imaging of GNP distributions in an animal 
using benchtop XFCT and conventional CT together. 3D volume rendering of the mouse from postmortem 
CT data along with smoothed XFCT images and corresponding axial CT images of the kidney and tumor 
slices (Reprinted with permission, Manohar et al. 2016).   
According to a recent experimental study (Manohar et al., 2018), a practical benchtop XFCT 
system with transmission CT capability can be built for whole-body imaging of small animals (e.g., 
~3-cm diameter mice) containing GNPs at relatively low concentrations on the order of several 
hundred parts-per-million (ppm) (e.g., 0.3 mg of GNPs per gram tissue). In general, such a 
benchtop XFCT system would be considered acceptable for in vivo imaging of small animals, if it 
could satisfy the realistic constraints of x-ray dose and scan time (e.g., less than ~40 cGy and 1 
hour per imaging session, respectively) for in vivo imaging.  
       
Current and future challenges 
Compared with synchrotron XFCT, benchtop XFCT is typically performed with relatively higher 
energy but less intense polychromatic x-ray sources, resulting in less efficient XRF photon 
production and detection. This aspect directly affects the material detection limit (or system 
sensitivity) at a given x-ray dose as well as the overall scan time (or data acquisition time) of a 
benchtop XFCT system. The consequences from this aspect are more pronounced for benchtop 
XFCT performed with relatively high x-ray tube voltages (e.g., > 100 kVp or average energy of 
~80 keV), due to increased scatter of higher energy photons that complicates the XRF signal 
extraction from the scatter background. Thus, there is a strong motivation to adopt 
monochromatic/quasi-monochromatic x-ray sources, if available on a benchtop setting, to 
overcome the inherent difficulties of benchtop XFCT. For example, published computational 
studies (Manohar et al., 2014; Ahmad et al., 2014) suggested more than one order of magnitude 
increase in the XRF signal per a given x-ray dose or the sensitivity, with the use of such x-ray 
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sources (vs. polychromatic x-ray sources) for excitation of gold K-shell XRF photons from a GNP-
containing small animal-sized phantom.    
 
Another critical technical challenge arises from the current difficulty in parallel acquisition (using 
array or pixelated detectors) of XRF signals, which would be essential to accomplish in vivo 
imaging of small animals using a benchtop XFCT system under the given constraints of x-ray 
dose and scan time. Additionally, XFCT requires fully spectroscopic data with sufficient energy 
resolution (e.g., < 1 keV energy bin), in order to achieve highly sensitive quantitative imaging of 
both known and unknown elements present within the imaging objects. For benchtop XFCT, this 
requirement has been met reasonably by adopting a commercial, energy-resolving, 
thermoelectrically-cooled, single-crystal cadmium telluride (CdTe) detector (Cheong et al., 2010). 
In fact, custom-array detectors (or multiple detectors working in parallel) using this detector can 
easily be adopted for benchtop XFCT, lowering the scan time and x-ray dose inversely 
proportional to the number of detectors (Jones et al., 2012). Nonetheless, there is a practical 
limitation for this approach in terms of the number of detectors that can be deployed into benchtop 
XFCT setups built on smaller footprints for the purpose of small animal imaging. Thus, despite a 
few known/expected difficulties (e.g., inferior energy resolution/charge sharing effect), pixelated 
detectors may be found more advantageous for parallel XRF signal acquisition than arrays of 
single crystal detectors. 
 
The remaining technological challenges for benchtop XFCT reside mainly with optimization of 
various hardware components and operating parameters. While not specifically 
discussed/referenced in this article, numerous investigations have contributed to research 
advances in these aspects. Additionally, there are a number of issues that are uniquely associated 
with in vivo imaging but have not been seriously investigated thus far. Such issues include 
application-specific optimization of metallic NPs (in terms of material/size of NPs as well as 
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conjugation of targeting moieties), multimodal (e.g., CT+XFCT) and/or multiplexed imaging, and 
effects of NP pharmacodynamics/pharmacokinetics on benchtop XFCT scanning and image 
reconstruction.          
 
Advances in science and technology to meet challenges 
Currently, laser-driven x-ray sources producing sufficiently intense monochromatic x-rays, based 
on inverse Compton scattering, are available on a relatively small footprint and have been 
considered for various applications including x-ray CT (Achterhold et al., 2013). Also, other special 
x-ray sources that offer quasi-monochromatic spectra based on intense XRF lines (von Busch et 
al., 2005; Hertz et al., 2014) have been used for benchtop XFCT. Although attractive in terms of 
their x-ray spectra, these sources are associated with some limitations (e.g., x-ray energy and 
flux/output, size, cost, etc.) similar to those of synchrotron XFCT, which may need to be carefully 
considered if benchtop XFCT is intended primarily for preclinical imaging.  Meanwhile, as practical 
alternatives, carefully designed metal filters, especially in conjunction with high-power (e.g., > 1 
kW) x-ray sources, or crystal-based approaches utilizing the Bragg diffraction (e.g., the use of 
highly oriented pyrolitic graphite), can also be pursued to tailor the polychromatic x-ray spectrum 
for benchtop XFCT imaging of high-Z probes including GNPs (Manohar et al., 2014).  
 
While readily available, typical pixelated photon-counting detectors provide only a limited number 
(~4-5) of rather broad energy bins/windows (in a few keV intervals) and, consequently, may not 
meet the detector specifications for ideal benchtop XFCT imaging. Nevertheless, there have been 
attempts to adopt some of them for benchtop XFCT (Yoon et al., 2016; Ren et al., 2016; Li et al., 
2017), providing some insight into the technical feasibility and reconfirming some benefits of 
benchtop XFCT previously demonstrated (e.g. better sensitivity than transmission CT) (Bazalova 
et al., 2012; Manohar et al., 2016). Overall, these initial attempts have commonly revealed 
somewhat expected consequences from the insufficient detector energy resolution, most notably 
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the difficulty in achieving highly sensitive benchtop XFCT. In theory, such consequences may be 
avoided or at least mitigated by adopting fully-spectroscopic pixelated detectors providing higher 
energy resolution than conventional photon-counting detectors (Seller et al., 2011). Nonetheless, 
it remains to be seen whether or not this expectation can be realized under the typical operating 
conditions for the whole-body imaging with benchtop XFCT.     
 
Considering the research advances on the two key issues discussed above (as well as other 
issues mentioned earlier but not specifically discussed here), it will soon be possible to produce 
a benchtop XFCT system (with simultaneous or sequential CT capability) that can allow for whole-
body imaging of live animals while meeting realistic scan time/x-ray dose constraints. A fully-
optimized benchtop XFCT system (with an ordinary polychromatic x-ray source) will likely enable 
several fold improvement in the sensitivity and scan time (e.g., detection limit of ~100 ppm of gold 
and less than ~20 minutes of scan time, in the case of GNP imaging), compared to the currently 
available systems.  
                   
Concluding remarks 
Benchtop XFCT is now nearing to become a practical preclinical imaging modality. Further 
improvement beyond the currently anticipated technical specifications would still be possible, 
depending on future research advances.            
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Micro- and Nanodosimetry of MNPs  
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Status 
In irradiated biological cells containing metallic nanoparticles (MNPs), the presence of the MNPs leads to a local 
enhancement of the radiation interaction probability. Generally, the atoms in the MNP have a higher atomic 
number (Z) than the atoms constituting biomolecules and water. Hence, they have higher interaction cross 
sections. Furthermore, radiation interaction with the MNPs not only leads to the production of additional 
secondary electrons but also to the occurrence of Auger cascades. Auger electrons with energies in the range 
of few keV deposit most of their energy in the 
proximity of the MNPs. This implies, in principle, that 
steep energy deposition gradients may occur as well as 
short-range changes of the radiation quality (particle 
track structure) on the nanometer scale (McMahon et 
al 2011). 
So far, the investigation of these physical radiation 
effects of MNPs has only been possible by numerical 
simulations using Monte Carlo codes. Until recently, 
many common Monte Carlo codes did not allow track 
structure calculation. Therefore, most published 
studies have focused on the calculation of the enhancement of the absorbed dose around the MNP, where 
results may differ by several orders of magnitude among the published studies even for similar simulated 
setups(Li et al 2020). Only few simulation studies have investigated other quantities like the radiation damage 
due to low-energy electrons which lead to clustered ionizations at the nanometric scale (Gargioni et al 2016, 
Dressel et al 2017, 2019). 
Current and future challenges 
Simulations of microdosimetric and nanodosimetric effects of MNPs face the same computational challenges 
as the host of simulations are aimed at determining the local enhancement of absorbed dose. The most 
important of these challenges is related to the small dimensions of the nanoparticles which imply a small 
probability for individual particle tracks or trajectories to intersect with the nanoparticle volume. Therefore, 
realistic simulations of physical radiation effects require the CPU-intense simulation of large numbers of primary 
particle histories or the application of suitable variance reduction techniques. However, seemingly 
 
Figure 1. Photon energy dependence of the number of 
photon interactions per absorbed dose in spherical gold 
nanoparticles of 50 nm and 100 nm diameter. 
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straightforward solutions such as reducing the incident field size may lead to simulation scenarios where the 
results are strongly biased by a lack of secondary particle equilibrium (examples can be found in (Li et al 2020, 
Dressel et al 2017)). For simulations of dose enhancement by MNPs in photon fields, the lack of contribution of 
energy depositions from secondary particles that would be produced in an extended radiation field by photon 
interactions outside the confined region of the simulated primary photon field, can be estimated from literature 
data of photon interaction cross sections (Rabus et al 2019). For track structure simulations, a corresponding 
correction approach may also exist but has not yet been identified. The multiscale nature of the problem means 
that there is a need to consider energy deposition within micro/nano-scopic dimensions across macroscopic 
length scales (Zygmanski and Sajo 2016, Martinov and Thomson 2016). 
Another computational challenge for micro- and nanodosimetry of MNPs is related to the fact that in addition 
to the stochastics of the electron tracks emerging from the MNPs, an additional stochastic factor comes into 
play which is related to the probability that an MNP in a biological cell interacts with the incident radiation. 
Figure 1 shows the photon energy dependence of the probability per dose that a single gold MNP of 100 nm 
and 50 nm diameter will experience a photon interaction. (This probability scales with the third power of the 
MNP diameter.) It is quite evident that for realistic values of absorbed dose the probability is generally 
significantly lower than unity such that the effect of the Poisson statistics of the photon interactions with the 
MNPs needs to be considered.  
For microdosimetric computations this may not be an issue if the considered targets (cell nucleus or 
chromosome domains) are large enough to contain a large number of MNPs. For smaller target sizes in the 
nanometer range and for nanodosimetry, on the other hand, there may be a need to focus on conditional 
specific energy distributions and cluster size distributions for the vicinity of particular MNPs (that experienced 
a photon interaction).  
In addition to these methodological issues, there is also the general challenge of computational micro- and 
nanodosimetry related to the different cross section models used by different codes and to potential additional 
interaction channels, such as collective excitations within the MNP (Verkhovtsev et al 2014). Different cross 
section models have been shown to lead to drastic differences particularly between results for nanodosimetric 
quantities (Villagrasa et al 2019). Additional quantum mechanical effects such as the Heisenberg uncertainty 
principle further challenge the accuracy at short length scales and very low energies (Thomson and Kawrakow 
2011, Liljequist and Nikjoo 2014). A proper assessment of the uncertainties of such simulation results probably 
cannot be only based on comparison of computational approaches. It will rather be necessary to develop and 
perform benchmark experiments that test the predictions of the codes. A more long-term challenge that goes 
even further would be the development of experimental approaches measuring nanodosimetric cluster size 
distributions in the presence of MNPs directly.  
Advances in science and technology to meet the challenges  
Several groups around the world are working on improving the cross-section data used in simulation codes for 
applications involving nanoparticles (Wälzlein et al 2014). Some of the augmented data sets include effects like 
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changes in the surface plasmons that were predicted theoretically (Verkhovtsev et al 2014). For the case of 
interactions of MNP with protons, experimental validation of the cross sections by comparison to direct 
measurements of the yield of emitted electrons has already been performed (Hespeels et al 2019). For photon 
irradiation, similar studies are in progress. Such experiments require a careful consideration of the stochastic 
aspects of the radiation interaction with MNPs.  
Direct measurement of the influence of MNPs on microdosimetric spectra have been proposed using avalanche-
confined tissue-equivalent proportional counters that are capable of simulating nanometric site sizes 
(Mazzucconi et al 2020). The idea is to build such detectors with an exchangeable cylindrical outer electrode 
and to use electrodes coated with MNP on the inner surface or incorporating MNPs in the material of the 
electrodes.  
Figure 2 shows illustrations of two other approaches to 
directly measure the enhancement of radiation effects 
by gold nanoparticles on DNA-based detector 
structures. The first approach is based on the so-called 
DNA-dosimeter concept where DNA strands are used 
as resistive elements in nano-circuits and strand breaks 
are detected by changes in the electrical conductivity 
(Heimbach et al 2017). In contrast to this early work, 
DNA scaffolds would be used to add MNPs in defined 
positions from the DNA conductors to study the change 
in yield of radiation-induced strand breaks in the 
presence of MNP in functional dependence on their 
distance from the target.  
The second approach illustrated in the lower panel of 
Figure 2 would use the DNA origami folding technique 
to produce a base from which oligonucleotides are 
protruding that are terminated by large molecules, 
such as biotin. These biotin molecules can be detected by atomic force microscopy (AFM). Here, radiation 
damage in form of DNA strand breaks would be detected (in a destructive manner) by the disappearance of 
object spots in the AFM images.  
The influence of MNPs would be studied in the same way as before, i.e. by comparing test structures without 
nanoparticles with structures where MNPs are incorporated at defined positions. The advantage of the second 
approach would be that measurements can in principle also be performed in a liquid-water environment to also 
study the influence of MNPs on the production of free radical species.  
 
 
 
Figure 2. Illustrations of two proposed experimental 
approaches for measuring the nanodosimetric effects of 
gold MNPs on DNA-based structures. For details see text.  
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Concluding remarks 
The envisioned experiments described above will not only be useful for validating simulations of the physical 
microdosimetric and nanodosimetric effects of MNPs but also, in the long run, such experiments may be further 
developed to provide a comprehensive set of benchmark data for the complete simulation chain, including the 
physical, physico-chemical, and chemical stages. This would allow fixing some of the simulation parameters 
such as, for instance, the contribution of molecular excitation by very low energy electrons to direct strand 
breaks or the probability of breaking the backbone chain by reactions with hydroxyl radicals. In this way, they 
may contribute to a synoptic picture of the radiation effects of MNPs that encompasses their physical, chemical 
and physico-chemical contribution to the radiobiological enhancement of irradiation on the micrometer and 
nanometer scale.  
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Status 
When localized in the vicinity of tumor cells, high Z metallic nanoparticles are thought to enhance 
energy deposition upon radiation treatment. One has first to distinguish between radiation types. keV 
photons often used in radiobiology studies cause the strongest effect: in this energy range, most of 
the interactions with the surrounding media occur via the photoelectric effect (PE) which is 
proportional to !³ #³$ . Accordingly, impinging photons trigger more interactions in metal material 
than in the surrounding water. The effect is further reinforced through the deexcitation cascade: the 
created vacancy will be filled by outer shell electrons, leading to the emission of characteristic X-rays 
or low energy Auger electrons. The combination of photoelectrons, Auger electrons and to a lesser 
extent characteristic X-rays is believed to add extra dose outside MNPs [1]. The effect is spread at the 
nanometer level (as the range of Auger electrons is limited to <100 nm) and extends micrometers 
away from MNP due to the other secondaries which typically have energies close to the primary 
photons.  For instance, the gold K-edge at 80.7 keV adds a boost in the PE coefficient if the primaries 
energy is chosen accordingly. However, in the MeV range, the mass absorption coefficient for water 
and gold are similar. The probability to enhance the deposited dose is then reduced and limited to the 
cascade effect upon gold ionization. The combination of photon radiation and MNP thus results in 
local radiation hardening and pushes the modality toward a high linear energy transfer (LET) type.  
The PE mechanism explained above is often put forward to justify the observed enhancement after X-
ray irradiation. Indeed, the ratio of the mass attenuation coefficient of gold to water can reach 160 
near the gold K-edge [2]. However, a number of experimental studies reported significant 
radiosensitization effects when gold nanoparticles (GNPs) were used at concentrations as low as 0.003 
% of gold per mass of tissue (weight percent, WP) [3]. Most simulation studies report predictions using 
typical 0.1 to 1 WP, an overrated amount when considering the possible transition to human medicine. 
According to this amount, it is possible to derive a more realistic mass attenuation coefficient for a 
homogeneous mixture of water and gold.  
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 Figure 1 (A) Mass attenuation coefficient for water (black), water with 1% gold mass (red) and water 
with 0.1% gold mass (green) (B) Mass attenuation coefficient for water (black), water with 1% gold 
mass (red) and corresponding ratio according to energy (blue) 
Figure 1A displays the mass attenuation coefficients with 1 and 0.1% gold mass. 0.1 WP is not sufficient 
to produce a significant change in the mass attenuation coefficient. However, the K and L edges of 
gold are discernible if the concentration is increased to 1 WP. The corresponding ratio is presented in 
Figure 1B, with a strong peak in the keV range as expected, although with a maximum twofold 
increase.  
In addition to limits in the gold amount uptake in cells, it has to be noted that the probability for a 
GNP to incur PE will not only depend on the gold mass attenuation coefficient but also on its size, with 
the smallest being the worst case. Lin et al. simulated the number of electrons produced through 
photon interaction with a directly targeted 50 nm GNP and reported values in the 10-5-10-4 range per 
incoming photon at best [4]. A similar finding was highlighted in a simulation study of McMahon et al. 
[5]. Over 99% of GNP present in a cell do not contribute to the dose enhancement effect, even if the 
few incurring ionizations produce dramatic spikes in dose. 
In the past decade, proton therapy centers flourished around the world and the question of dose 
enhancement thanks to GNP was raised again. The radioenhancement mechanism provided by GNPs 
originate from mere gold ionizations (with associated cascade), the stopping power in gold being 
greater by a factor from 2 to 10 compared to water. However, the qualities of generated electrons 
differ according to the energy spectra of incoming protons. The maximum energy transferred to an 
electron at rest is given by %&'( = *+,&-²/0,123 02,3,	, with M and V the mass and the velocity of the proton, 
respectively, m the mass of the electron and g the relativistic factor. In patients, most created 
electrons have energies in the range of hundreds of keV near the proximal end of the tumor while rare 
A B 
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electrons reach a few keV at the distal end. The result is again radiation hardening but in a very 
localised fashion around GNPs, giving rise to local high dose peaks.         
Given their higher LET and ionization density, the number of projectiles required to achieved a 
therapeutic dose of 2 Gy is quite small (about 200 for 25 keV/µm protons, depending on cell size) and 
unlikely to hit nanoparticles at all [6]. Although higher energy protons are more numerous for a 2 Gy 
dose, this low interaction probability is not increased, given the lower stopping power. Indeed, for 
protons in the 1-250 MeV range the secondary electron emission due to GNP was found to be 
insignificant compared to the keV photon modality [7]. Similarly, Lin et al. reported very low 
interactions probabilities per Gy for SOBP protons (~10-8 to 10-4 for the 2-50 nm GNP range) [8, 9].  
 
Current and future challenges  
In general, biologically observed enhancement values are higher than predicted [10].  
However, Monte Carlo codes used to compute these predictions often rely on incomplete Auger 
cascades. For instance, the deexcitation module after proton ionization in Geant4 is only available up 
to the M shell. Vacancies created in outer shells are thus not followed and the potential increase in 
dose is not taken into account. This is not a major issue for photon irradiation simulations. However, 
medium and high LET protons are unable to ionize inner shells as they deliver a few keV at most and 
most ionizations will take place in the outer shells. Moreover, Auger relaxation is the most probable 
in this case, as its probability increases with increasing shell number (fluorescence yield = 0.0245 for 
the M shell in gold).  It is thus very likely that proton simulations performed with Geant4 so far 
underestimated the yield of Auger electrons for high Z targets.     
In addition, some codes, like Geant4, rely on condensed history models. These models are more 
adapted for macroscopic volumes and electron tracking for energies above a few hundred keV. Geant4 
models G4BetheBlochModel and G4BraggModel do not take into account the generation of electrons 
below the mean ionization potential of the medium (790 eV for gold) which leads to an 
underestimation of low energy electron yield. This underestimation has been recently highlighted by 
comparison with experimental results for proton impact on gold nanoparticles. To reproduce low 
energy electron emission spectra from a gold target, a single interaction approach, like the one used 
in TRAX, NOREC and Geant4-DNA, should be preferred [11, 12].  
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 Advances in science and technology to meet challenges 
The reliability of track structure codes depends on the implemented interaction cross section sets 
which are not easily accessible for low energy projectiles. Validation for the TRAX cross sections has 
been performed indirectly by reproducing experimental data of backscattered electron emission from 
gold film and GNPs [13]. Since the electron energy distribution is anisotropic, data are still needed in 
the forward direction where a larger amount of high energy electrons is expected.  
As pointed out in numerous experimental works, the spatial distribution of GNPs in cells is not 
homogenous as assumed in many simulation studies. Aggregation of GNPs is often observed and could 
decrease radioenhancement by trapping produced electrons hence adding a buffering effect. Accurate 
representations such as GNP packing in vesicles distributed in cytoplasm should be preferred [14].  In 
addition, there is a crucial need for the modelling of more realistic geometries at the cell level, with a 
detailed description of components such as organelles or DNA structure.  TOPAS-nBio was recently 
released to help the understanding of radiobiological processes at the cell and sub-cellular levels, also 
including a large set of chemical reactions [15]. The inclusion of the cytosol scavenging properties 
would represent another step forward.  
Current findings also raise questions concerning the radiosensitization mechanism which do not seem 
to be solely driven by physical effects. The great disparity between physical dose enhancement 
predictions and the experimentally observed radiosensitization effects suggests a biological 
component to the radiosensitization mechanism. Increasing evidences supporting this concept are 
piling up highlighting the key role played by the oxidative stress in the radioenhancement effect. In 
recent articles, Daems et al. and Penninckx et al. demonstrated that gold nanoparticles have the ability 
to inhibit thioredoxin reductase (TrxR) and gluthatione reductase, regulators of redox reactions, in 
cancer and normal cells [16-18]. TrxR inhibition induces a cell weakening effect prior to radiation 
exposure, which if timed wisely can lead to a radiosensitization effect. In the context of personalized 
medicine, genomic assays for mRNA TXNRD1 expression in tumor biopsies can thus drive the 
application of GNP radiosensitization in the clinic.      
 
Concluding remarks 
The preceding discussion points out that although there is a moderate radioenhancing effect 
demonstrated for keV photons, additional dose deposited when using MeV photons or protons is 
limited. The development of single interaction Monte Carlo simulations and accurate geometries 
should shed light on this matter. However, the biological component seems preponderant in the MNP 
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action mechanism. More studies are needed to assess the impact of MNP on biological pathways in 
the absence of radiation, such as regulation of genes involved in DNA repair, slowing down of cell 
proliferation or disruption of the cellular redox balance. The scientific community should thus 
reconsider the original theory of physical enhancement and encompass the role of MNPs on decreased 
detoxification potential of cells.   
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Status 
It is well known that electrons are emitted from the impact of energetic particles or photons on a 
metal surface. A similar behavior is expected from a metal nanoparticle (MNP) [1,2]. For photons, the 
mass-energy absorption coefficient is larger by roughly two orders of magnitude in the 10-80 keV 
range, compared to that of biological tissue [3]. The yield of emitted electrons, which extends from a 
few eV to energies close to the primary photon energy [2], is proportionally increased in magnitude. 
However, the electron energy distribution depends not only on the material, but also on the size and 
shape of the MNP. Electrons emitted with energies above the ionization potential of the medium 
produce a further generation of lower energy electrons. For initial charged particles, the secondary 
electron distribution lies essentially in the low-energy (0-30 eV) range due to their production via the 
excitation of plasmons in the MNP [4]. According to recent calculations, the number of these low 
energy electrons (LEEs, < 30 eV) produced by high-energy protons interacting with a gold NP (GNPs) 
would be about an order of magnitude higher than that from an equivalent water volume and not 
very dependent on the primary particle energy [4]. In contrast, the high electron-emission efficiency 
of X-ray-irradiated MNPs is restricted to initial energies below 300 keV [3].  
Considering the range of electrons in water [5] and the spherical geometrical factor, most of the 
LEE density lies within submicrometer distances from the surface of a MNP irradiated with fast 
charged particles or 10-80 keV photons [1, 2]. These LEEs are the most numerous reactive species 
created around the MNP and carry a large portion of the energy absorbed by the metal. They strongly 
react with the surrounding medium, mainly via a resonant interaction, which leads to their temporary 
capture by  molecules or moieties of large biomolecules. This capture leads to the formation of 
molecular transient anions (TA) that decay by reemitting the captured electron (i.e., autoionization) 
or by dissociating (i.e., dissociative electron attachment) [6]. Since autoionization can leave the target 
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molecule in a dissociative electronic state, both channels can break bonds and damage biomolecules 
[6]. However, in complex molecules, such as DNA, electron transfer between basic units increases the 
complexity of the damage mechanism [7]. 
During the last two decades, there have been numerous experimental and theoretical studies on 
the interaction of LEEs with gaseous or complex condensed biomolecules, ranging from amino acids, 
peptides, DNA bases, sugar and phosphate groups, to oligonucleotides of short DNA strands and 
bacterial DNA [6-10]. The condensed-phase targets usually consisted of self-assembled monolayers 
and multi- or sub-monolayer films of the biomolecule deposited on a conductive substrate. The type 
of LEE-induced damages in DNA, analyzed by various techniques, included single and double strand 
breaks, base damage and cleavage, and clustered lesions, consisting of single strand breaks and base 
damages [6,7,10]. From yields vs energy curves, it was generally concluded that the decay of TAs into 
destructive channels played a major role in inducing these lesions [6-9]. 
 Fig. 1 shows damage enhancement factors (EFs) resulting from irradiation of DNA-GNP complexes 
with 60-keV electrons. In these experiments, 5-nm diameter GNPs were bound in ratio 1:1 to plasmid 
DNA [10]. For production of a potentially lethal lesion, such as a DSB, bare GNPs produce an EF of 
about 2.3, as shown by the left column (blue) of the middle group in Fig. 1. With GNPs coated with 
ligands of 2.5 to 4 nm, the corresponding EFs for DSBs are reduced to 1.5 (green column) and 1.0 (red), 
respectively. This result corroborates theoretical predictions on the electron distributions from fast 
charged particles [4], as it implies that energetic electrons interacting with MNPs generate essentially 
LEEs of extremely short ranges (<10 nm).  When a similar experiment is performed with 200-keV X-ray 
irradiation of 5-30 nm diameter PEG-coated GNPs, longer ligands (~11 nm) are needed to obtain only 
a 60% reduction in EF [11], as expected from the larger thermalization range of the X-ray 
photoelectrons [2,4,5]. 
Current and future challenges: 
Despite the numerous publications that have appeared in the last decade on MNPs, we still don’t 
have any experimental results showing the actual distribution of electrons emitted from isolated 
MNPs of different sizes, interacting with various types of high-energy ionizing radiation. The present 
electron distributions rely on theoretical and model calculations [1,2, 4]. Many parameters need to be 
included and refined in these calculations, so that, both at the experimental and theoretical level, the 
generation of accurate electron distributions in biological media remains a challenge. 
The efficient use of MNPs in Radiotherapy is limited by the nanoscale range of most emitted 
electrons and their secondaries, unless the MNPs can be targeted to vital cellular molecules, such as 
DNA. Otherwise, the MNPs only serve to increase the energy deposited and radicals randomly created 
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in the cytoplasm or outside the cell. Moreover, to take advantage of the high electron-emission 
coefficient of 10-80 keV photons, conventional X-ray Radiotherapy must be limited to superficial 
tumors. 
Advances in science and technology to meet the challenges 
Electron-energy distributions emitted from irradiated gaseous MNPs could be measured using high-
resolution electron energy analysers. Photoemission spectra measurements of free core–shell 
nanoparticles [12] and X-ray photoelectron spectroscopy of isolated NP beams [13], which already 
exist to investigate X-ray photoelectron emission from non-metallic NPs of different sizes, could 
possibly be adapted to vaporized MNPs. On the other hand, the present distributions could be 
improved by more elaborate calculations of (1) the slowing down of electrons within the MNP, 
particularly in the low-energy regime; (2) the number of electrons emitted per initial interaction, (3) 
the number of electrons that recombine with the MNP and (4) the interaction with the MNP of 
electrons backscattered around and into the nanospheres. In such computations in biological media, 
it would be advantageous to consider the electrostatic potential created between the MNP and the 
escaping electron, including the charge-induced polarization of the medium and the multiple positive 
charges created in the MNP, which in turn influence the number and energy of emitted electrons. 
Targeting of specific components of cancer cells (e.g., the nucleus) is possible with vector molecules 
that bind to MNPs [14,15]. However, for maximum efficiency, the MNP should be either coated with 
the shortest possible ligand, or be only partially coated, to reduce as much as possible, attenuation of 
Figure 1. EFs for the formation of SSBs, DSBs and loss of initial 
DNA configuration induced by 60 keV electrons in GNP-DNA 
complexes with ratio 1:1. In each group of three histograms, 
the EFs correspond to enhancement factors for a specific DNA 
damage, when GNPs of 5 nm diameter bound to DNA are bare 
or coated with C11H23 or DTDTPA (i.e., dithiolated diethylene 
triaminepentaacetic) ligands. 
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the short-range highly-destructive LEEs. Finally, it should be noted that efficient X-ray therapy need 
not be limited to superficial tumors, if the MNP is accompanied by a therapeutic radioisotope. In other 
words, MNPs could improve localization of radiation energy in targeted radionuclide therapy (TRT) 
[15,17,19], where the emitted short-range particles are often accompanied by the emission of longer-
range photons [16] that could be partially absorbed by the metal and produce LEEs. GNPs have already 
been complexed with chelators that bind to Auger-electron and beta-particle emitters used in TRT 
[15,17]. Encapsulation of such radionuclides in gold nanocages was also suggested to convert into LEEs 
particle radiation and the accompanying photon flux, which reaches healthy tissues during TRT [18]. 
 
Concluding remarks and acknowledgments 
Considering future quantification of the species produced around irradiated MNPs and ongoing 
refinement in the methods of targeting them to cancer cells, via intravenous administration of carriers 
[15, 19, 20] or direct intratumoral injection [21, 22], such particles should become highly efficient for 
treating tumors and their metastasis. These methods are also promising for extending the field of 
radiobiology to the nanoscopic level.  
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Status 
The Monte Carlo (MC) method is a class of computational methods that simulates a process by 
randomly sampling its variables. For the modeling of Metallic Nanoparticle (MNP) effects, the radiation 
transport is simulated by 
sampling the probability density 
functions (PDFs) of various 
electromagnetic interactions. MC 
codes use two types of transport 
calculations: The condensed 
history (CH) approach groups 
multiple scattering processes 
together to reduce computation 
time for larger volumes, whereas 
the discrete model simulates the 
track structure (TS) event-by-
event to calculate radiation 
interactions stepwise on a micro- 
and nanometer-scale. Examples 
of TS codes are NOREC, PARTRAC, 
KURBUC, TRAX, NASIC, general-
purpose MC codes using CH are 
EGS and FLUKA, and PENELOPE, 
MCNP and Geant4, which have also been extended with TS simulation capabilities for to low-energy 
processes in cellular media (Incerti, 2016a and references therein). The Geant4-DNA TS extension, for 
example, simulates electron interactions down to a few electronvolt (eV) in liquid water and has 
Fig. 1 a) MC codes simulate radiation transport by numerically 
calculating the change in position r, momentum p and energy E. The 
transport of a 1 MeV proton through a 20 nm gold nanoparticle 
surrounded by water is shown for MC simulation using b) only CH 
physics processes in 10 nm steps (Geant4 Livermore EM physics), c) 
using TS in water (Geant4-DNA) and d) with water radiolysis included. 
Transport 
particle
Sample 
interaction 
from PDF
Simulate 
interaction
Update E 
and start 
new step 
Sample 
distance 
from PDF
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electrons
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become popular in the medical physics research community as its features are also readily available 
through user-friendly interfaces such as TOPAS and GATE. MC simulations have been used to obtain 
electron emission spectra and radial dose distributions for single or clustered MNPs (26Fe, 47Ag, 64Gd, 
78Pt and 79Au) for various geometrical parameters and radiation modalities (Zygmanski and Sajo, 
2016, McMahon et al 2015). 
While the physical dose enhancement by MNPs might be negligible for megavolt photons and particle 
beams, their impact in the chemical stage might be significant (Rudek et al 2019). Several MC codes 
offer simulation of radiolysis in a pure water environment (PARTRAC, Geant4-DNA, TRAXchem, 
KURBUCchem, RITRACKS and TOPAS-nBio). The increase in yield of radical oxygen species (ROS) scales 
with the physical dose enhancement when radial dose distributions are folded with radiolysis 
simulations in the surrounding water (Tran et al 2016). Experimental work demonstrated adverse 
effects such as catalytical production of hydroxyl at GNPs and binding of scavengers but also beneficial 
effects such as a reduction of ROS by superoxide dismutase or peroxide catalase. The actual chemical 
reactions of ROS and scavengers at the MNP surface are so far ignored in all MC codes. As MC codes 
already struggle with computational costs of pure water radiolysis, an implementation of such surface 
reactions that depend on dose, temperature and the chemical environment will dramatically increase 
the parameter phase space and is unlikely to happen anytime soon. 
Recently, the microscopic dose distribution shifted into focus to investigate biological effects of GNP 
distributions on cellular structures. The sensitivity enhancement predicted with an adaptation of the 
local effect model produced higher sensitization with kilovolt photons if GNPs were internalized into 
the cell (McMahon et al 2011). However, sensitization for megavolt photons and protons was only 
significant when GNPs were internalized into the nucleus (Lin et al 2015a). Organelles other than the 
nucleus such as the mitochondrial DNA may also be considered a target because some GNP 
configurations accumulate on the surface of mitochondria leading to locally increased energy 
deposition within the organelle (McNamara et al 2016, Kirkby and Ghasroddashti 2015). Imaging the 
experimental GNP distributions as input for MC simulations showed how important the geometry of 
radiosensitive structures and GNP clustering is for the prediction of cell survival (Sung et al 2018). 
Similarly, high dose spikes at the vascular wall, especially for hypo-fractionated treatment, have been 
found for accumulation of GNPs in the vesicles as typically observed in in-vivo experiments (Lin et al 
2015b). 
  Simulations of macroscopic GNP distributions have also been carried out to show pathways of 
clinical translation. In virtual phantom scenarios, photon beam energies were optimized for arc therapy, 
and found to be dependent on GNP uptake, beam arrangements, and patient geometries (Koger and 
Kirkby 2018, Sung and Schuemann 2018).  
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Current and future challenges 
Currently, TS MC codes are limited to simulations in water. Physics models need to consider the full 
deexcitation of electronically-excited heavy elements such as via long Auger cascades, simulate 
discrete ionization events and electron transport with low cut-off energies and benchmark these 
processes with updated cross section databases and scattering experiments on metallic 
nanostructures.  
In addition, more systematic experiments are necessary to describe the chemical processes with MNPs. 
MC codes need to be extended to the chemical stage as recent experiments point out a significant 
impact of nanoparticles on radiolysis and scavenging of ROS. The implementation of selected test cases 
orientated on experimental benchmarks promises a major step forward in understanding the indirect 
effect by MNPs.  
One significant challenge is that the calculation speed is slow not only for chemistry but already when 
only taking into account discrete physical processes compared to the condensed history approach. 
Ultimately, the MC codes will be compared to experiments in living material. Cellular structural 
information is still limited due to current imaging capabilities. For example, transmission electron 
microscopy (TEM) only provides 2D structures for dead cells. Fluorescence probes may alter the 
original physiological conditions of the cell. Moreover, those studies are restricted only for in-vitro cell 
experiments. 
 
Advances in science and technology to meet challenges 
Recently, the full deexcitation cascade in GNPs can be activated in Geant4, however, the initial 
ionization is limited to the K, L and M shells and the increase in total emitted energy was below 1% for 
all tested modalities (Incerti, 2016b). Discrete electron transport in gold has been implemented in 
Geant4-DNA and will be available in a future release (Sakata et al 2018). Recent versions of MCNP6 
and PENELOPE include extended cross-sections down to 10 eV and 50 eV and calculate slightly higher 
doses than Geant4-DNA within the first few nm from the surface of the GNP (Jung et al 2018). Discrete 
electron transport in copper is available in PARTRAC (Dingfelder and Travia 2015) and an extension to 
gold is expected soon. However, molecular dynamics approaches such as the MBN Explorer will 
possibly allow to analyze the structure, composition and dynamics of atomic clusters and coated 
nanoparticles (Solov'yov et al 2012). 
For ionization by particle beams, a discretization is not yet implemented in Geant4 and the cut-off at 
rather high mean ionization energies in the Bethe-Bloch theory for heavy elements compared to light 
elements is a possible source for the underestimation of dose enhancement observed for MNPs. A 
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discretized ionization model based on cross sections calculated in the Binary Encounter Approximation 
as used in TRAX showed an increase of low-energy electron emission (<1 keV) of up to two orders of 
magnitude (Hespeels, 2019) which will push the overall dose enhancement closer to enhancements 
observed in cell experiments with particle beams. An inter-comparison such as the recent exercise by 
the EUropean RAdiation DOSimetry (EURADOS) group is a helpful approach to ensure quality control 
of new implementations and various available codes. (Li et al n.d.) 
Additionally, full track structure simulations with a mechanistic approach will offer a different method 
to the phenomenological models in the simulation setup. This approach may provide more 
mechanistic biological endpoints such as DNA breakages (J Schuemann et al 2018).  
To improve the computational speed, new codes written for Graphics Processing Unit (GPU) cards have 
been developed and cloud computing, wherein computing resources are allocated from a third party, 
can also resolve the computational costs in track structure Monte Carlo simulations (Wang et al n.d.). 
For a more realistic simulation setup, advanced molecular imaging is necessary to acquire more 
accurate 4D cellular structures. Clinical trials of nanoparticle-mediated radiotherapy will offer data on 
tumor control probability and normal tissue toxicity. Using imaged biodistributions in Monte Carlo 
simulations will help to interpret these new data. 
 
Concluding remarks 
Monte Carlo simulations provide a comprehensive description of physical dose enhancements by 
MNPs. Advances in the physics modeling will further improve the accuracy especially in the low-energy 
range. The future challenge, however, lies in the implementation of indirect pathways via ROS and the 
modeling of biological damage and repair. Both approaches require substantial improvement of the 
underlying models, the available cross sections and the efficiency of the calculation. Future Monte 
Carlo studies should then be carefully designed to complement in-vivo and in-vitro observations. 
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Abstract: 
Nanoparticle enhanced radiation therapy is a breakthrough in the development of cancer treatment, 
which mainly aims at enhancing radiation effects (called radio-enhancement) in tumors selectively and 
can at the same time be used for tumor diagnosis or drug delivery using the same agent. The underlying 
principle of NP radio-enhancement is the amplification of radiation induced electron emission into a 
nanoscale volume using efficient electron emitters such as high-Z compounds, thereby amplifying the 
induction of lethal (complex) biological damage and the biological efficiency of radiation treatments. 
Various experimental and theoretical studies consolidated this description. However, the role of water 
radicals issued from the interaction of electron with surrounding water molecules, and, more 
surprisingly, the influence of molecular oxygen on the chemical reactions consecutive to the NP 
activation, are not yet much described in the existing models. This overview summarizes the chemistry 
that counts for the radio-enhancing effects of NPs.  
 
Status: 
Tumor targeting of radiotherapy treatments and improvement of the therapeutic index for 
radioresistant cases remain great challenges. Adding nanoparticles able to improve radiation effects 
(radio-enhancers) into tumors is proposed as a promising strategy. The principle of this method is to 
use high electron emitters to amplify the local electron emission when activated by ionizing radiation. 
So far, complexes or nanoagents composed of high-Z atoms such as gold, platinum, gadolinium (AGuIX 
in particular, see Lux et al. (Lux et al 2018)) or hafnium have proven to be efficient radio-enhancers 
(Lux et al 2018, Porcel et al 2010, Bonvalot et al 2017). The advantage of small nanoparticles compared 
to metallic complexes stems from their capacity to concentrate in tumors via the Enhanced and 
Permeability Retention Effect (EPR). They also offer a high flexibility of surface functionalization, which 
allows implementing various modalities within the same agent (MRI by adding paramagnetic atoms, 
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PET using isotopes, cell imaging or other fluorescent based techniques by grafting various fluorescent 
markers) (Truillet et al 2016). The fast development of a radio-enhancement strategy – already used 
in clinic (see F. Lux et al. (Lux et al 2018)) – requires better understanding and simulation of the 
phenomenon with the goal to improve the design of new nanoagents and an implementation of this 
strategy in treatment planning systems. The difficulty of this work stems from the multiscale character 
of the phenomenon ranging from the early stage activation of the processes (<10-16 sec, nanoscale) to 
the impact in vivo (minutes to hours, macroscale). In between these scales sits the chemistry stage, 
which is often absent from the models although it is expected to play a crucial role in the observed 
outcome.  
Below, the stages of radio-enhancement in the presence of NPs are described. The third and fourth 
steps are present in all radiation schemes of biological systems but were not yet investigated in the 
presence of NPs. Figure 1 illustrates the physical and chemical stages expected in the NPs induced 
radio-enhancement. 
 
 
Figure 1: Representation of chemical reactions induced after activation of NPs and consecutive 
amplification of electron emission: from water radiolysis to the production of water radicals and the 
induction of oxidized byproducts. 
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Step 1: Physical stage 
The physical stage of the radio-enhancement effect has been extensively described and reviewed 
(Kuncic and Lacombe 2018).  
Briefly, the radio-enhancement is attributed to a local amplification of electron emission due to the 
high ionization cross section of high-Z atoms compared to water. The activation of NPs by incident 
photons is initiated via the photoelectric effect for photons of energies below approx. 100 keV, and 
Compton effects for photons of higher energies. NPs may also be activated by incident charged 
particles, namely fast ions (protons or carbon ions as used in proton-and hadron-therapy), or electrons 
produced in the medium. In this case, Coulombic interactions are responsible for the activation of NPs 
(Kuncic and Lacombe 2018, Lacombe et al 2017). This model explains the improvement of radiation 
effects observed when NPs are added in the treatment of animals by x-rays or protons (Hainfeld et al 
2004, Kim et al 2010). This effect was found to be correlated with the amplification of tumor cell killing 
when cells are treated with NPs prior to irradiation (Butterworth et al 2010). Using biomolecular 
probes in solution (without any metabolic effect), it was shown that the induction of nanosize lesions 
is enhanced in the presence of NPs (Butterworth et al 2008, Porcel et al 2012). This demonstrated the 
physical character of the NPs induced amplification of radiation lethality. 
 
Step 2: Chemical stage – water radiolysis 
The production of water radicals by photon, ion or electron irradiations and the impact on living 
organisms is a very well-known phenomenon. In contrast, very few studies focused on the relative role 
of water radicals versus the role of the direct interaction with incident radiation in the radio-
enhancement effect. The amplification of the radical production by NPs has been evidenced in 
experiments performed in water (Sicard-Roselli et al 2014) and in solution containing biomolecules 
(Porcel et al 2010). The few studies performed with cells using radical scavengers reported that, on 
average, hydroxyl radicals (OH), the most powerful oxidants of water derivatives (E°'=(•OH/OH-) = 1.90 
V at pH=7), account for 60-90% of the amplification of cell killing induced by high-Z compounds 
activated by high energy photons or ions (Usami et al 2008, Jeynes et al 2014). In parallel, it was 
demonstrated that the increase of nanosize lesions (>2 nm) is also due to OH (Porcel et al 2010, 
Butterworth et al 2008, Porcel et al 2012). So, the production of hydroxyl radicals is a key component 
of the radio-enhancement phenomenon. So far, very few simulation studies exist that consider this 
stage in simulation models (e.g. Geant 4 DNA (Schuemann et al 2019) and references therein, and TRAX 
for incident ion effects (Boscolo et al 2018)). 
 
Step 3 and 4: Chemical stage – production of organic radicals and peroxidation 
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The chemistry that follows the production of hydroxyl radicals, strongly depends on the presence of 
molecular oxygen in biological systems. This phenomenon is well documented (Chapman et al 1973, 
Edwards et al 1984). However, the influence of NPs on these chemical reactions has never been studied 
nor even considered as important factor. In the view of future prospective, we remind here the basic 
principles of the chemistry that could be impacted by the presence of NPs.  
 
Hydroxyl radicals (•OH) produced during the radiolysis phase (step 2) rapidly and efficiently undergo 
reactions with the main organic constituents (RH) of biological systems, namely, nucleic acids, proteins 
and lipids. These reactions lead to the production of carbon-centred radicals (R•) through hydrogen 
atom abstraction of a range of aliphatic or conjugated substrates RH. These species (R•) are highly 
reactive and short-lived (t1/2 < 5 ms in mammalian cells in complete absence of oxygen). R• have a high 
affinity for O2 yielding peroxyradicals (ROO•). This reaction is in competition with the annihilation of R• 
by electron donors (radical scavengers) that afford a high degree of radioprotection.  
The interaction of hydroxyl radicals (•OH) with DNA (Chapman et al 1973, Cadet et al 2005) and with 
lipids (Sevanian and Hochstein 1985) has been extensively reported. Peroxyradicals formed from DNA 
(ROO• with R corresponding to a nucleic acid chain) decay through bimolecular, tetroxide-based 
pathways in pyrimidines or 2'-deoxyribose ending in alcohols, aldehydes, cetones or bond breakage 
with frequent release of superoxide (O2•-) and oxygen in the singlet excited state (1O2). Owing to lateral 
diffusion in phospholipid membranes, peroxyradicals formed from unsaturated lipids, namely lipid 
peroxyl radicals (ROO• with R corresponding to a lipidic chain) are able to abstract a hydrogen atom 
from other lipid molecules initiating a chain reaction. Chain termination is achieved by interaction of 
ROO• with scavengers (i.e. H•) yielding alkyl hydroperoxides (ROOH) or by radical-radical recombination 
yielding organic peroxides (ROOR) (Sonntag 1987). Disproportionation may also take place. Little is 
known of the fate of peroxyradicals formed from proteins. The well-known radiosensitizing effect of 
oxygen stems from these chemical cascades. Consistently, the partial pressure of oxygen in irradiated 
tissues is a crucial determinant of radiosensitivity. pO2 ranges between 1 and 10% in normal tissues, 
which defines normoxia, whilst the presence of hypoxic regions in solid tumors (pO2 < 0.5%) explains 
the low therapeutic index of radiotherapy.  
 
One study already reported that NPs have low effect when cells are irradiated in anoxic conditions (pO2 
close to 0) (Jain et al 2014). This result questions the efficiency of NPs to improve the treatment of 
hypoxic cancer cases. Thus, further experiments are needed to better characterize and quantify the 
effects of NPs depending on the cell type (if any) and their chemical environment. The localization of 
NPs in cell compartments (nucleus, lysosomes, mitochondria) may influence this effect.  
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In summary, the chemistry involved in NP induced radio-enhancement is crucial to characterize with 
the goal of designing more competitive agents and monitoring their impact in various tissues. This 
requires new investigations and theoretical models, which enclose reactions driven by water radicals 
and by molecular oxygen. 
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Modelling the Biological Effects of Metal 
Nanoparticles 
Stephen McMahon1 
1Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7AE 
 
Status 
The use of metal nanoparticles to enhance radiation therapy was originally proposed on very 
simple physical grounds – due to their high density and atomic number, heavy metals 
absorbed significantly more radiation than soft tissue, increasing the dose deposited and 
improving clinical outcomes. This effect can be readily quantified using Monte Carlo 
modelling on the macro- (Cho 2005, McMahon et al 2008) and nano-scales (Jones et al 2010, 
McMahon et al 2011). 
However, while significant radiosensitisation was observed experimentally, it rapidly became 
clear that the observed effects differed significantly from those predicted on this simple 
physical basis. Two major observations were made: i) many experiments reported 
significantly greater enhancements than those predicted by physical dose modification alone; 
and ii) significant enhancement was observed with megavoltage photon irradiations, with 
only negligible differences in dose deposition (Chithrani et al 2010, Jain et al 2010, 
Butterworth et al 2012). These observations have been confirmed in numerous systems, 
clearly demonstrating that biological processes underlie experimental radiosensitisation, 
schematically illustrated in Figure 1. However, the exact nature of these processes is not well 
known. A range of different possibilities have been implicated by different studies, with some 
of the main candidates illustrated in Figure 1. 
Additional sensitisation due to nanoscale dose enhancement has been by far the most 
extensively modelled process. As described elsewhere, models of MNP-radiation interactions 
make it clear that they have a highly heterogeneous impact on dose distributions on the 
nanoscale (Jones et al 2010, McMahon et al 2011). Analogies were drawn between these 
dose distributions and charged particle therapy, where similar sub-cellular localisation of 
dose leads to greater biological effects (Christian et al 2018).  
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These effects have been extensively studied in charged particle therapy, with a number of 
models proposed to understand these effects, such as the Local Effect Model (LEM) (Elsässer 
et al 2008) and the Microdosimetric Kinetic Model (MKM) (Hawkins 2003). These models 
have been applied to GNP-enhanced therapy, and demonstrated MNP dose heterogeneity 
leads to greater biological effects and increased sensitisation for a range of radiation types 
(McMahon et al 2011, Lechtman et al 2013, Lin et al 2014).  
However, such approaches involve assumptions about the uptake and distribution of MNPs 
throughout the cell which are not readily verified experimentally. While some progress has 
been made through the use of detailed cell-level imaging enabling the prediction of cell-
specific dose distributions and associated radio-sensitisation effects, it is increasingly 
apparent that nanoscale dosimetry cannot explain the full variation of experimental data.  
A major limitation of these models is that they typically consider MNPs as otherwise inert 
modifiers of radiation dose, in contrast with experimental data showing that MNPs can 
modify a range of chemical and biological processes. These effects may further modulate the 
radiosensitivity of cells. For example, many nanoparticle preparations have significant 
physico-chemical activity, acting as both sources and scavengers of free radicals (Ionita et al 
2008), which is known to significantly impact on the yield and type of DNA damage, 
potentially driving sensitisation at all energies. 
Even in the absence of radiation, MNPs are not biologically inert, and have been shown to 
impact on cells in a range of lethal and sub-lethal fashions. These include the induction of 
DNA damage as single agents (Kang et al 2010), upregulation of cell death pathways 
(Djurišić et al 2015), and disruption of oxidative stress regulation (Dayem et al 2017). These 
effects have been shown to sensitise cells to other DNA damaging agents, underscoring that 
MNPs can affect response even in the absence of physical dose modification (Zheng and 
Sanche 2009, Jain et al 2010). 
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Despite the importance of these effects– particularly at clinically-relevant energies – they are 
much less understood than physical dosimetry, and have seen little or no quantitative 
modelling. This represents a significant limitation in our understanding of MNP-based 
therapies.  
 
Current and Future Challenges 
A major challenge in modelling MNP sensitisation is the extreme heterogeneity of particle 
types and model systems. While a small number of commercial MNPs have been used in 
multiple studies, most studies use locally-produced nanoparticles, frequently with specifically 
developed coatings and targeting molecules. While the dosimetric impact of these particles is 
not significantly affected by this functionalisation, it can profoundly change their biological 
activity. While uptake and localisation can be incorporated in physical dosimetry, purely 
biological effects are not meaningfully represented. In addition, the majority of published 
studies focuses on limited endpoints (e.g. cell killing). Together, this means there is 
insufficient evidence to fully characterise cellular toxicity and radiation sensitisation, and 
identify underlying mechanisms for each nanoparticle preparation. This challenge is 
compounded by the difficulty of translating in vitro observations into in vivo systems. Here, 
differences in the pharmacokinetics of different preparations and their impact through the 
course of a full treatment schedule must also be taken into account. 
As a result, modelling in this area remains under-conditioned, with ad-hoc analysis of limited 
datasets producing models which are in reasonably good agreement with fitting data, but 
Figure 1 Left: Interplay between physical and biological sensitisation. Although MeV physical enhancement is expected to be 
only a few percent of keV enhancement, megavoltage sensitisation has been reported (squares: Chithrani 2010, circles: Jain 
2010), indicating a large component of biological sensitisation. The absolute and relative magnitudes of the physical and 
biological effects are strongly MNP dependent, and are not easy to extrapolate between systems. Right: Illustration of 
possible drivers of radiationsensitisation in MNP-treated cells. These range from well-understood physical processes (top) to 
biological effects with almost no modelling (bottom). 
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which do not translate effectively to other systems. This approach is unlikely to generate 
models with wider applicability to support the development and optimisation of novel MNP 
treatments.  
 
Advances in science and technology to meet challenges 
The most efficient way to characterise a single nanoparticle preparation, remains an ad-hoc 
approach – that is, treating the nanoparticles as simple dose-modifying agents, using standard 
techniques to measure the additive and synergistic effects of the MNPs with radiation, and 
fitting a suitable empirical model. This has the advantage of being simple, and less 
experimentally demanding. Studies of the dependence of MNP radiosensitisation on 
irradiation type and energy may also enable a separation of “physical” and “biological” 
components of sensitisation. However, such ad-hoc approaches are not suitable for more 
general predictive tools. Instead, more general predictions require the development of 
relevant, systematic, mechanistic models to enable the integration of many heterogeneous 
datasets to produce useful predictions for a range of MNP.  
A number of groups are beginning to develop tools which may address some of these 
limitations. For example, realistic Monte Carlo models of cellular DNA may enable the 
accurate prediction of radiation-induced DNA damage, integrated with models of free radical 
chemistry to incorporate radiation indirect effects (Meylan et al 2017, Lampe et al 2018). As 
these models mature, they may offer the capacity to incorporate MNPs as mediators of both 
direct and indirect damage providing a natural opportunity to understand these effects. 
By contrast, models of purely biological mechanisms of MNP radiosensitisation remain 
limited. Although a number of individual models have considered some mechanistic aspects 
of DNA repair (Taleei and Nikjoo 2013, McMahon et al 2016, Henthorn et al 2017), in many 
cases these cannot easily incorporate the biological perturbations introduced by MNP. As a 
result, alternative approaches may be required to fully understand MNP radiosensitisation.  
Systems biology and machine learning techniques present one alternative to more 
mechanistic model development. While these approaches have not seen wide application in 
MNP radiosensitisation, they have been applied to understand nanoparticle uptake and 
toxicity (Winkler et al 2014, Costa and Fadeel 2016). These may provide a framework to 
enable the complexity of cellular biology to be incorporated alongside mechanistic physical 
predictions in MNP radiosensitisation. 
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Concluding Remarks 
While it is clear that a large portion of MNP radiosensitisation is driven by biological effects 
which are largely independent of the physical dose modification, modelling in this area 
remains a significant weakness. Designing an optimised nanoparticle therapy necessitates the 
development of new approaches. This may involve the development of more mechanistic 
descriptions of MNP-cell-radiation interactions, or machine learning and systems biology 
approaches to leverage heterogeneous datasets for novel insights.  
Regardless of the approach, there remains a pressing need for more high-quality, systematic 
experimental investigation of the impact of MNP across all stages of radiation response. 
Moreover, efforts should be made to present data in as accessible a format as possible, to 
enable incorporation of these disparate datasets in unified models. 
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Molecular Mechanisms of Metal Nanoparticle 
(MNP)-Mediated Radiation Enhancement 
Karl T. Butterworth1 and Kevin M. Prise1 
1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom. 
 
1. Status 
The unique physicochemical properties of high atomic number (Z) metal nanoparticles 
(MNPs) have made them attractive as potential radiosensitizers in cancer radiotherapy based 
on their strong photoelectric absorption coefficients in comparison to soft tissue. Since the 
seminal study by Hainfeld and colleagues [1], which demonstrated a significant increase in the 
survival of mice irradiated following injection of 1.9 nm gold nanoparticles (GNPs), a large 
body of preclinical evidence gained across multiple different MNPs, tumour models and 
radiation sources, has demonstrated the clear potential of MNPs as radiosensitizers [2,3]. 
However, these data are confounded as the majority of experimental observations cannot be 
accurately predicted from physical parameters including mass energy absorption and MNP 
concentration. This raises important questions concerning the underlying mechanisms of MNP-
mediated radiosensitization which is not primarily driven by increased total dose delivered to 
target cells [2].  
Over the past decade, the field has made concerted efforts aiming to resolve the 
disparity between predictions of MNP radiosensitization and observed biological effects. This 
has involved detailed studies of the underlying molecular mechanisms of MNP 
radiosensitization for gold, silver, platinum, hafnium and gadolinium particles. Our group has 
largely focussed on understanding the radiobiological effects of gold nanoparticles (GNPs) in 
studies using model systems which have evolved from simple plasmid DNA through to cellular 
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systems and in vivo tumour models (Butterworth et al 2008, Jain et al 2011, Butterworth et al 
2016). For the first time, we demonstrated GNP-mediated radiosensitization at MV energies, 
an unexpected finding due to the dominance of Compton effects in the MV energy range which 
are unrelated to Z, and strongly implicated biologically driven radiosensitisation [5].  
Subsequent reports from our laboratory and others have aimed to delineate the 
molecular mechanisms of MNP-mediated radiosensitization (Reviewed in Butterworth et al 
2012, Rosa et al 2017). The majority of experimental reports have highlighted oxidative stress, 
DNA damage response and cell cycle effects as critical response mechanisms (summarised in 
figure 1). Furthermore, we reported that significantly elevated levels of DNA damage may be 
a direct result of impaired mitochondrial functional manifested by increased oxidation and loss 
of membrane potential [8].  
Considering the broad range of experimental parameters and end-points investigated, it 
is difficult to draw overall conclusions on a critical mechanism of action for MNP- mediated 
radiosensitization. Clearly, the underlying mechanisms are the products of multiple and 
complex physical, chemical and biological interactions, that ultimately result in enhanced cell 
killing and have implications for the radiosensitivity, repair, reassortment, repopulation and 
reoxygenation of tumour cells [9]. Importantly, these effects need to be better resolved to 
improve the translation of MNPs to clinical evaluation and in realising their promise in cancer 
radiotherapy. 
 
Current and future challenges  
Despite a significant body of evidence demonstrating the potential of MNPs to enhance 
radiation response, only a very small number of agents have progressed to clinical trials. These 
include nanoparticle formulations of gold (CYT-6091, Cytimmune, NCT00356980; 
NCT00436410), gadolinium (AGuIX, NH TherAguix, NCT02820454; NCT03818386; 
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NCT03308604) and hafnium oxide (NBTXR3, Nanobiotix, NCT01433068; NCT02721056; 
NCT02805894). Preclinical studies have provided considerable insight into the molecular 
mechanisms of MNP radiosensitization, yet there remains a number of considerable challenges 
to be addressed if the successful translation of investigative new MNPs to early phase trials is 
to improve. 
One of the greatest challenges preventing MNPs from entering the clinic is the need for 
a more comprehensive delineation of the impact of their physicochemical characteristics on 
radiobiological response. The wide-ranging properties of MNPs that have been investigated in 
radiation studies prevent a general description of the underlying mechanisms of 
radiosensitization, which is a significant limitation in optimising MNP-based therapy. We have 
begun to understand the influences of element, size, shape, surface modification and source 
energy. As an example, our group demonstrated the thiol coating on a commonly used 
commercial 1.9 nm GNP to significantly modulate cellular pathways relating to oxidative 
stress, and inhibition of this effect almost entirely abrogated the radiosensitizing effect of the 
GNP [10]. A precise understanding of how these variables control key biological interactions 
and cellular localisation is required to inform the optimum physical parameters of MNPs, but 
as of yet these have not been systemically investigated in standardised cell models.  
Considering nuclear DNA as the critical target of radiation induced damage, it would 
be expected that the subcellular localisation of MNPs would have a major impact on 
radiobiological response. In particular, it may be expected that proximity to the nucleus is 
critical due to the short range of Auger electrons emitted which cause a series of clustered 
ionising events around the nanoparticle [11]. Using a soft X-ray microbeam targeting nuclear 
or cytoplasmic cellular compartments, our group demonstrated that even in the absence of 
nuclear localisation, cytoplasmic irradiation can drive significant DNA damage, again 
identifying the mitochondria as a central mediator in GNPs radiosensitization [12]. These data 
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raise intriguing questions concerning subcellular localisation and critical organelle targets for 
MNP effects, which will require more sophisticated imaging methods if they are to be better 
understood. 
Finally, most MNPs rely on the enhance permeability retention (EPR) effect for tumour 
specificity due to abnormal vasculature. The development of improved methods for tumour 
targeting has the potential to make a significant impact and lead to the application of MNPs for 
precision medicine. For example, HER-2 targeted MNPs for use in breast cancer have been 
postulated to have potential [13], but to date none of the many potential approaches in this area 
have translated to the clinic. 
 
Recent advances in science and technology to meet challenges 
The future success of MNPs in the clinic is predicated on a more detailed mechanistic 
understanding of the impact of key physical variables on cellular interactions and how these 
determine cellular radiobiological response. As frequently occurs, technologic evolutions lead 
to transformative impacts on scientific research, which will continue to propagate discovery in 
the MNP research field.  
Recent advances in gene expression technologies such as single cell sequencing allow for 
studies of the genomic and transcriptomic landscape of tumours at the single cell level [14]. 
This approach could provide critical insight in the multicellular complexity of MNP 
radiosensitization along with spatial information about tissue context or volumetric localization 
of gene expression changes. Advanced gene and protein-based methods may be used to 
characterise alterations in immune cell types and improve understanding of interactions 
between MNPs, the immune system and tumours. In the immunotherapy era, this approach 
may be central to identifying novel opportunities for combining MNPs with immune-oncology 
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agents. Finally, these approaches could also identify biomarkers for the selection of patients 
most likely to respond to MNP enhanced radiotherapy. 
There is also a need to apply improved preclinical models to demonstrate the 
radiobiological effects of MNPs in tumours and normal tissues. Approaches could include the 
use of standardised cell models, syngeneic transplants or patient derived tumour models 
established in humanised host animals. Tumour response data should be supported by 
evaluation of MNP effects in disease relevant organs at risk, all of which should be evaluated 
using precision small animal image guided radiotherapy [15]. These developments are likely 
to synergise with new tools for improved theoretical modelling of MNPs utilising relevant, 
systematic, mechanistic models and enabling the integration of many heterogeneous datasets 
to produce useful predictions for a range of different MNP. The integration of these approaches 
will undoubtedly improve our understanding of the fundamental processes underlying MNP 
radiosensitization, leading to improved, biologically optimised treatments. 
 
4. Concluding remarks 
Technological advances and improved understanding of mechanisms of cellular 
radiobiological response will continue to play critical roles in improving the efficacy of 
radiotherapy. MNP agents have high potential to increase the therapeutic index and impact 
standard of care in clinical oncology, yet there remain critical challenges towards clinical 
translation. Addressing these challenges requires a multidisciplinary strategy focused on 
applying state-of-the-art technologies to better understand the physical, chemical and 
biological basis of MNP radiosensitization, and ultimately deliver optimised therapies to the 
clinic. 
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Figure 1. Schematic illustration of the physics processes (panel A) and molecular mechanisms 
(panel B) of MNP-mediated radiation enhancement. 
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Optimization of GNP-based Cancer Therapeutics   
B. Devika Chithrani, Kyle Bromma 
Department of Physics and Astronomy, University of Victoria, Victoria, BC, Canada; devikac@uvic.ca 
Status 
Over 20 years ago, it was demonstrated that iodine is a radiosensitizer of cells in culture[1]. It was also 
found that direct injection of iodine into tumors followed by radiotherapy (RT) suppressed the growth of 
80% of tumors[2]. More recently, gold has been pursued as a radiosensitizer due to its higher atomic 
number compared to iodine (ZAu=79 vs. ZI=53) and favorable biocompatibility[3]. The high atomic number 
of gold nanoparticles (GNPs) means that they can enhance the effective radiation dose at the site of 
disease. During radiation therapy, the presence of GNPs enhances the cross section of low-energy 
electrons and other cell damaging species leading to increased cell death[4, 5]. This strategy is already 
being used by many groups to develop novel cancer treatments and the initial results are extremely 
promising[6]. The ultimate goal of these GNP-based platforms will be the targeted delivery of tumors 
using radiotherapy while causing minimal side effects to normal tissue.  
Current and future challenges 
Irradiation with kilovolt X-rays following intravenous administration of 1.9 nm GNPs to mice bearing 
subcutaneous tumors was the first study to show an increased radiosensitization effect in tumors[3]. A 
comparison of the mass concentrations of iodine and gold across different studies suggests that in the 
absence of intracellular uptake, in vivo intra-tumoral concentrations of ~5 !""  were required for 
radiosensitization[7]. In contrast, whenever GNPs were internalized in vitro, radiosensitization was 
achievable at concentrations as low as 1 #"" 	[8]. Based on these recent observations, the current 
challenge is to achieve radiosensitization effects at dramatically lower concentrations through 
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intracellular localization of GNPs within the solid tumor issue. 
 
Figure 1. Roadmap to optimizing GNP-mediated radiation response. Accumulation of a higher percent of 
injected NP dose within the tumor cells involves enhanced blood circulation of NPs, penetration within the 
tumor tissue once they leave the leaky tumor blood vessels, and finally internalization of GNPs within every 
tumor cell. The ultimate goal is to enhance the DNA damage using GNPs as a radiosensitization agent. 
 
Advances in science and technology to meet the challenges 
Advances in building novel lipid-based platforms for efficient intracellular delivery of GNPs has shown 
remarkable results[9]. This can also be achieved through optimizing physicochemical properties of GNPs 
for individual particle delivery[10].  Successful delivery of GNPs into the intracellular space of individual 
cells also depends also on the efficiency of crossing a few boundaries, including tumor blood vessels to 
tumor tissue followed by their penetration successfully through the tumor tissue as illustrated in Figure 
1. A tumor with a well-developed collagen network or extracellular matrix (ECM) can be considered to be 
physically resistant to NP-based therapies[11, 12]. For tumors with a strong ECM, treatments that reverse 
or inhibit collagen production and assembly could be performed prior to NP-based therapies [11]. Hence, 
downregulation of ECM may become a promising adjuvant therapeutic strategy for ECM-rich tumors [12]. 
Another approach could be to use ECM-degrading enzymes to modify the collagen structure to further 
improve the distribution of NPs in solid tumors.  
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Features of solid cancers not accounted for by three-dimensional (3D) in vitro models are variable 
interstitial fluid pressure (IFP), the influence of convection, and stromal cells[13]. Although direct in vivo 
assessment has the advantage of duplicating the clinical environment more closely, these 3D in vitro 
models offer the advantage of being able to examine and evaluate isolated results with less complicated 
parameters[14]. As illustrated in Figure 2, a recent study has shown that the size and surface functionality 
of the NPs could be tailored using these 3D in vitro models to produce a higher accumulation within the 
tumor in an in vivo tumor model[15].  
 
Figure 2. Optimization of NP-based delivery systems at monolayer and tissue-like multilayer models leads to their 
successful accumulation in in vivo models. 
 
Radiation therapy, in particular, damages cancer cells with a less pronounced effect on the 
vasculature[16]. It has been shown that nano-sized molecules enter radiation-treated tumors at a rate 
2.2-fold higher than non-irradiated tumors[17]. Radiation killed well-oxygenated cancer cells near tumor 
blood vessels leading to higher vascular permeability[16].  However, excessive radiation damage to blood 
vessels can shut down blood flow, which affected the nano-therapeutic agent delivery negatively. 
Moreover, the effects of radiation on the ECM must be considered since radiation could damage the long 
polymer chains of hyaluronan and elastin resulting in premature stiffening of tissue[18]. Hence, the effect 
of radiation on the ECM and tumor blood vessels should be taken into account when designing NP-based 
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treatment protocols. In addition, rapid tumour growth results in leaky vessels allowing NPs to leak into 
the tumour and NPs are retained due to the lack of a functional lymphatic system. However, the lack of 
lymphatic drainage within the tumour also increases IFP which can also limit delivery of therapeutic 
agents[13]. Hence, it could be important to consider administration of agents that renormalize 
vasculature temporarily to improve the blood flow [13, 19].  
Concluding remarks 
The incorporation of cancer nanomedicine into current therapeutic protocols requires the careful 
consideration of multiple factors to overcome the barriers for intracellular NP delivery within the tumor. 
Three-dimensional tumor models could be further improved to test NP-based therapeutics in parallel to 
animal models to improve our understanding and overcome barriers to NP transport while understanding 
the mechanisms of tumor cell death in a less complex tumor microenvironment. Introduction of GNPs to 
current chemoradiation protocols could potentially be another addition to the current toolbox that could 
benefit some patients[20]. Most of the in vitro and in vivo data have shown promising results with clinically 
relevant MV photon beams and lower concentration of GNPs. Hence, clinical translation of GNP-mediated 
radiosensitization could be achieved with a collective effort from research groups around the world.   
 
References 
[1] H. Matsudaira, A.M. Ueno, I. Furuno, Iodine Contrast Medium Sensitizes Cultured Mammalian Cells 
to X Rays but Not to X Rays, Radiat Res, 84 (1980) 144-148. 
[2] R. Santos Mello, H. Callisen, J. Winter, A.R. Kagan, A. Norman, Radiation dose enhancement in 
tumors with iodine, Med Phys, 10 (1983) 75-78. 
[3] J.F. Hainfeld, D.N. Slatkin, H.M. Smilowitz, The use of gold nanoparticles to enhance radiotherapy in 
mice, Phys Med Biol, 49 (2004) N309-315. 
[4] Y. Zheng, L. Sanche, Low Energy Electrons in Nanoscale Radiation Physics: Relationship to 
Radiosensitization and Chemoradiation Therapy, Rev. Nanosci. Nanotechnol., 2 (2013) 1-28. 
[5] J.D. Carter, N.N. Cheng, Y. Qu, G.D. Suarez, T. Guo, Nanoscale Energy Deposition by X-ray Absorbing 
Nanostructures, J. Phys. Chem. B, 111 (2007) 11622-11625. 
[6] J. Schuemann, R. Berbeco, D.B. Chithrani, S.H. Cho, R. Kumar, S.J. McMahon, S. Sridhar, S. Krishnan, 
Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization, International Journal of 
Radiation Oncology • Biology • Physics, 94 (2016) 189-205. 
Page 88 of 128AUTHOR SUBMITTED MANUSCRIPT - PMB-109530.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
us
cri
pt
[7] J.H. Rose, A. Norman, M. Ingram, C. Aoki, T. Solberg, A. Mesa, First radiotherapy of human metastatic 
brain tumors delivered by a computerized tomography scanner (CTRx), Int J Radiat Oncol Biol Phys, 45 
(1999) 1127-1132. 
[8] X. Zhang, J.Z. Xing, J. Chen, L. Ko, J. Amanie, S. Gulavita, N. Pervez, D. Yee, R. Moore, W. Roa, 
Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles, Clin Invest Med, 31 (2008) E160-
167. 
[9] K. Bromma, K. Rieck, J. Kulkarni, C. O’Sullivan, W. Sung, P. Cullis, J. Schuemann, D.B. Chithrani, Use of 
a lipid nanoparticle system as a Trojan horse in delivery of gold nanoparticles to human breast cancer 
cells for improved outcomes in radiation therapy, Cancer Nanotechnology, 10 (2019) 1. 
[10] J.M. Bergen, Gold Nanoparticles as a Versatile Platform for Optimizing Physicochemical Parameters 
for Targeted Drug Delivery, Macromolecular bioscience, 6  506-516. 
[11] P.A.B. Netti, David A.; Swartz, Melody A.; Grodzinsky, Alan J.; Jain, Rakesh K., Role of extracellular 
matrix assembly in interstitial transport in sold tumors, Cancer Research, 60 (2000) 2497-2503. 
[12] T.L. Ji, Jiayan; Wang, Jing; Cai, Rong; Zhang, Yinlong; Qi, Feifei; Zhang, Lijing; Zhao, Xiao; Wu, 
Wenjing; Hao, Jihui; Qin, Zhihai; Zhao, Ying; Nie, Guangjun, Designing liposomes to suppress 
extraceullular matrix expression to enhance drug penetration and pancreatic tumor therapy, ACS nano, 
11 (2017) 8668-8678. 
[13] A.I.T. Minchinton, Ian F., Drug penetration in solid tumours, Nature Reviews Cancer, 6 (2006) 583-
592. 
[14] D. Yohan, C. Cruje, X. Lu, B.D. Chithrani, Size Dependent Gold Nanoparticle Interaction at Nano-
Micro Interface Using both Monolayer and Multilayer (Tissue-Like) Cell Models, Nano-Micro Lett., 8 
(2016) 44-53. 
[15] C. Yang, K. Bromma, B.D. Chithrani, Peptide Mediated In Vivo Tumor Targeting of Nanoparticles 
through Optimization in Single and Multilayer In Vitro Cell Models, Cancers, 10 (2018) 84. 
[16] Y.M. Nakamura, Ai; Choyke, Peter L.; Kobayashi, Hisataka, Nanodrug Delivery: Is the Enhanced 
Permeability and Retention Effect Sufficient for Curing Cancer, Bioconjugate chemistry, 27 (2016) 2225-
2238. 
[17] H.R. Kobayashi, Koen; English, Sean; Yordanov, Alexander T.; Milenic, Diane E.; Sowers, Anastasia L.; 
Citrin, Deborah; Krishna, Murali C.; Waldmann, Thomas A.; Mitchell, James B.; Brechbiel, Martin W., 
Application of a macromolecular contrast agent for detection of alteration of tumor vessel permeability 
induced by radiation, Clinical cancer research, 10 (2004) 7712-7720. 
Page 89 of 128 AUTHOR SUBMITTED MANUSCRIPT - PMB-109530.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
u
cri
pt
[18] F.B. Mohamed, D.A.; Winlove, C.P., Effects of ionizing radiation on extracellular matrix, Nuclear 
Instruments and Methods in Physics Research Section A, 580 (2007) 566-569. 
[19] R.T.B. Tong, Yves; Kozin, Sergey V.; Winkler, Frank; Hicklin, Daniel J.; Jain, Rakesh K., Vascular 
normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient 
across the vasculature and improves drug penetration in tumors Cancer Research, 64 (2004) 3731-3736. 
[20] S. Jelveh, D.B. Chithrani, Gold Nanostructures as a Platform for Combinational Therapy in Future 
Cancer Therapeutics, Cancers, 3 (2011) 1081-1110. 
 
 
Page 90 of 128AUTHOR SUBMITTED MANUSCRIPT - PMB-109530.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pte
d M
an
us
cri
pt
Targeting Tumor Vasculature with Nanoparticles for 
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Status 
Limitations of some nanoparticle-based cancer therapies include inadequate diffusion into the tumor interior 
and poor tissue penetration of stimulating agents (optical, IR, UV, kV x-rays, etc.). While relying solely on the 
inherently leaky tumor vasculature limits nanoparticle delivery to tumor cells, this challenge can be turned into 
an advantage by targeting tumor vasculature. Nanoparticles of a certain size tend to be trapped in tumor blood 
vessels and nanoparticle design can further enhance vascular 
accumulation. Situations in which passive tumor targeting 
confronts various physiological barriers (e.g. vascular walls, tissue, 
collagen, ECM matrix, etc.), nanoparticles actively targeted to 
tumor blood vessels have direct access to the therapeutic target. 
Several peptides have been introduced to actively target tumor 
endothelial cell receptor expression, increasing accumulation in 
these sites. For example, Arginine-Glycine-Aspartic Acid (RGD) has 
been shown to increase the nanoparticle concentration in and near 
tumor endothelial cells (1) (Figure 1).  
Tumor endothelial cells provide reliable receptor expression 
compared to other tumor cellular targets. In cancer cells, receptor 
expressions and density can vary depending on the tumor type, origin, stage, and mutational characteristics. All 
these factors make tumor endothelial targeting a more consistent approach across different disease sites. In 
addition, the range of the local radiation dose enhancement – and subsequent biological damage - via the 
production of low energy electrons (2) is relatively low (several microns), meaning that nanoparticles need to 
be close to the target cells. Therefore, vascular targeted nanoparticles will confer major damage to tumor blood 
vessels after irradiation. 
 
Figure 1. TEM imaging of tumor 
endothelial cell uptake in a mouse 
tumor model. Vascular targeted gold 
nanoparticles are shown in tumor 
endothelium 1 h after IV administration. 
Magnified images show uptake via 
clathrin/caveolae vesicles. Reprinted with 
permission from (Kunjachan Nano Letters 
2015). Copyright 2015 American 
Chemical Society. 
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There is strong evidence that tumor vasculature plays an important role in radiation therapy (3-5). Garcia-Barros 
et al. proposed that damage to tumor vasculature during radiation therapy may be more therapeutically 
beneficial than clonogenic cell death (3). A review by Park et al. presented experimental evidence linking 
radiation-induced tumor vascular damage to the success of stereotactic body radiation therapy (SBRT) 
procedures (5). Similarly, vascular disruption of hepatocellular carcinoma with injected Y-90 microspheres is a 
proven clinical technique (6).  
The concept of targeting tumor vasculature with nanoparticles to amplify radiation dose for vascular disruption 
was first proposed by Berbeco et al.(7). It has since been demonstrated that radiation therapy combined with 
vascular-targeted gold nanoparticles destroys tumor endothelial cells while largely sparing normal tissues (8, 
20). In that work, gold nanoparticles were targeted to tumor blood vessels via RGD prior to radiation therapy. 
Imaging and histology assays demonstrated the endothelial cell damage and subsequent vascular disruption 
(Figure 2). This group also demonstrated increased model nanodrug delivery after vessel disruption, suggesting 
a benefit for combined therapies (20).  
Vascular therapies improve the effects of 
radiation therapy (9). Preclinical experimental 
results indicate a synergistic relationship 
between vascular disruption and radiation 
therapy (10). However, no clinical trials have 
yet been reported with chemical vascular 
disrupting agents (VDAs) and radiation 
therapy. Negative results of a Phase 3 trial of 
chemical VDAs with chemotherapy (11) have 
been attributed to clinical factors (12). Using 
targeted GNPs rather than chemical VDAs 
should reduce off-target toxicities because 
GNPs are inactive outside the high radiation 
volume. 
 
Current and Future Challenges 
Changes in tumor physiology after vascular disruption may present both benefits and challenges for radiation 
therapy. For example, tumor vascular disruption may increase hypoxia. Hypoxic tumor regions represent 
 
Figure 2. Vascular disruption after delivery of targeted gold 
nanoparticles and radiation therapy. Endothelial destruction is 
observed via histopathology and confocal microscopy.  
(from Kunjachan Scientific Reports 2019) 
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resistant cell populations requiring additional therapeutic attention and failure to address hypoxia has 
implications for tumor therapy response as well as metastatic potential. The hypoxic conditions that are 
associated with tumors create a cellular response in which alternative metabolic pathways are enabled by 
factors such as HIF-1α which has been shown to be an exclusive regulator of carbonic anhydrase 9 (CA IX) 
activation. CA IX is largely absent from normal tissues and its over-expression is a clinical biomarker for poor 
prognosis (13).  
The tissue penetration of high energy (MV) photons is an advantage of external beam radiation therapy (EBRT) 
as a nanoparticle “activating” agent. These photons have significant skin sparing properties and deliver >60% of 
their maximum dose at 10 cm depth, for example. However, the penetration benefits of the high energy beam 
are somewhat mitigated by the physical interaction properties. The probability of a photoelectric interaction 
between an atom in the nanoparticle and an incident photon is proportional to 1/E3, where E is the energy of 
the incident photon. EBRT beams are composed of a spectrum of photon energies peaking well outside the 
range of photoelectric interactions (e.g. 6 MV). For this reason, combining nanoparticles with EBRT has been 
dismissed as impractical(14). However, roughly 95% of clinical radiation therapy procedures utilize this energy 
range, therefore a solution is necessary for nanoparticles to be clinically translated.  
 
Advances in Science and Technology to Meet Challenges 
The advancement of non-invasive hypoxia imaging will provide an opportunity to study temporary and 
permanent physiological changes within the tumor microenvironment to better understand the effects of 
nanoparticle targeted vascular disruption therapies. Current modalities for hypoxia identification include 
oxygen electrodes for direct measurement of pO2 levels, exogenous markers such as HIF-1α, and imaging 
modalities such as positron emission tomography (PET) and magnetic resonance imaging (MRI). Although 
oxygen electrodes provide a direct pO2 measurement, readings are limited to invasive, point measurements. 
HIF-1α and pimonidazole are used currently in clinical practice, however the results are limited to the area of 
the biopsy. PET imaging with hypoxia specific radiotracers such as [18F] labeled misonidazole (FMISO) is non-
invasive but is limited due to the cost as well as permeation limitations of small molecules. In the preclinical 
setting, there are additional optical imaging methods to image CA IX expression in vivo(15). An emerging 
noninvasive modality is functional MRI based diffusion-weighted (DWI) and blood/tissue oxygen level 
dependent (BOLD/TOLD) imaging. Both use gradient echo pulses to image the relative paramagnetic properties 
of oxygenated and deoxygenated hemoglobin within the whole tumor (16). Advantages of MRI-based 
approaches include non-invasive, serial imaging capabilities and translational potential to human scales.  
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Once the time-course of induced hypoxia has been identified, new techniques can be used to mitigate the 
therapeutic impact. Identification of these regions has begun transitioning cancer therapy towards improving 
tissue oxygenation. Current clinical trials are underway studying the use of hypoxia-activated prodrugs such as 
tirapazamine, hyperbaric chambers, and radiation dose painting based on hypoxia maps. Other strategies 
include increasing hypoxic cell radiosensitivity via misonidazole, decreasing oxygen consumption via metformin, 
and specifically targeting hypoxia surface markers such as HIF-1α (17).  
There is ample evidence that disrupting tumor blood vessels can increase drug delivery, improving outcomes 
(18). Ultrasound stimulated microbubbles (USMB) is a well-researched preclinical approach and has resulted in 
positive clinical results of a Phase 1 trial (19). USMB vascular modulation is limited, however, as it is not 
appropriate in all parts of the body. Published work with vascular-targeted gold nanoparticles demonstrated 
increased perfusion of an injected dye after disruption (20) (Figure 2) and further quantification by optical and 
MR imaging showed increased permeability and accumulation of model nanodrugs (20). Recent advances in 
drug nanoformulations will improve tumor delivery, particularly after vascular disruption.  
While EBRT beams peak at high energies, they also contain substantial contributions of low energy photons. Key 
radiation treatment planning parameters will also affect the proportion of low energy photons at the site of 
disease (21). At the patient surface, the fraction of low energy (<150 kV) photons is small (0.5%). Due to 
scattering processes, this increases to 8% at 10 cm depth and 11% for a flattening filter free (FFF) beam. 
Additional modifications of the linear accelerator can be made to further increase the low energy photon 
content without compromising the overall dose conformity (22).  
Concluding Remarks 
Recent studies have demonstrated the therapeutic benefit of targeting tumor blood vessels with nanoparticles 
prior to radiation therapy. Induced hypoxia after vascular disruption needs to be considered and mitigating 
actions should be included if needed. While preliminary results indicate that the subsequent vascular disruption 
will increase model drug delivery, careful studies in advanced translational models should be undertaken to fully 
understand the combined impact on tumor growth. The tools for these steps are currently available and 
therefore it is anticipated that clinical translation of this therapeutic approach will follow.   
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Clinical Translation of Gold Nanoparticles for 
In-Vivo Use 
Jason R. Cook1 and J. Donald Payne2 
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2 Aurorad, Inc, Houston, TX 77054 
 
Status 
Currently there are 12 active or completed clinical trials involving gold nanoparticles 
listed on clinicaltrials.gov, as shown in Table 1. Despite a slow start, clinical translation of gold 
nanoparticles is accelerating toward the clinic, led by Clene Nanomedicine who is actively 
recruiting for Phase 2 clinical trials. Unlike many of the other technologies which utilize IV 
delivery, CNM-Au8 is orally administered and does not suffer from many of the off-target 
accumulation issues associated with systemic delivery. However, this is still a very significant 
milestone because it marks the first gold nanoparticle technology to move into Phase 2 
effectiveness studies. 
 
Table 1:  List of active or completed clinical trials of gold nanoparticles from clinicaltrials.gov. 
Clinicial 
Trial 
Identifier 
Year 
Listed 
Phase Sponsor/Company Material Conditions 
NCT00356980 2006 Phase 1 
NIH Clinical Cancer 
/ Cytimmune 
Aurimune:  
TNF-target 
conjugated and 
PEGylated gold 
nanosphere 
Unspecific Adult 
Solid Tumor 
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NCT00436410 2007 
Early 
Phase 1 
NIH Clinical Cancer 
/ Cytimmune 
Aurimune:  
TNF-target 
conjugated and 
PEGylated gold 
nanosphere 
Adrenocortical 
Carcinoma, 
Breast Cancer, 
Colorectal Cancer, 
Gastrointestinal 
Cancer, 
Kidney Cancer, 
Liver Cancer, 
Melanoma (Skin), 
Ovarian Cancer, 
Pancreatic Cancer, 
and 
Sarcoma 
NCT00848042 2009 
Not 
Applicable 
Nanospectra 
Biosciences 
AuroLase:  PEG 
coated gold 
nanoshell 
Head and Neck 
Cancer 
NCT01270139 2011 
Not 
Applicable 
Ural Medical 
University 
Silica-gold 
nanoparticle 
Cardiovascular 
NCT02680535 2016 
Not 
Applicable 
Nanospectra 
Biosciences 
AuroLase:  PEG 
coated gold 
nanoshell 
Neoplams of the 
Prostate 
NCT02837094 2016 Phase 1 
Cardiff University / 
Midatech Pharma 
MidaCore 
MTX102:  
~1.5nm 
diameter Gold 
nanoparticle 
coated with 
Type 1 Diabetes 
Page 99 of 128 AUTHOR SUBMITTED MANUSCRIPT - PMB-109530.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ac
ce
pt
d 
an
us
cri
pt
C19-A3 
peptides, L-
glutathione, 
and glucose 
NCT02755870 2016 Phase 1 
Clene 
Nanomedicine 
CNM-Au8:  
~10nm 
diameter Gold 
Nanocrystal 
Healthy 
Volunteers - Male 
and Female 
NCT03020017 2017 
Early 
Phase 1 
Northwestern 
University 
Gold 
Nanoparticles 
coated with 
NU-0129 
Spherical 
Nucleic Acid 
Gliosarcoma 
Recurrent 
Glioblastoma 
NCT03669224 2018 
Not 
Applicable 
Cairo University 
Nano Care 
Gold: Gold and 
silver 
nanoparticles 
suspended in 
70% isopropyl 
alcohol 
Dentistry 
NCT03536559 2018 Phase 2 
Clene 
Nanomedicine 
CNM-Au8:  
~10nm 
diameter Gold 
Nanocrystal 
Relapsing 
Remitting 
Multiple Sclerosis, 
Optic Neuropathy, 
and 
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Optic Neuritis 
With 
Demyelination 
NCT03843710 2019 Phase 2 
Clene 
Nanomedicine 
CNM-Au8:  
~10nm 
diameter Gold 
Nanocrystal 
Amyotrophic 
Lateral Sclerosis 
NCT03815916 2019 Phase 2 
Clene 
Nanomedicine 
CNM-Au8:  
~10nm 
diameter Gold 
Nanocrystal 
Parkinson's 
Disease 
 
 
Current and future challenges 
Despite more than 50,000 articles listed on Google Scholar with the keywords gold 
nanoparticles and in vivo, no gold nanoparticle-based intervention has received FDA approval 
for clinical use. Many of these technologies could have significant clinical merit, but that alone 
is not enough to garner clinical translation. Most of the work with gold nanoparticles has been 
performed in academic laboratories, and in order to achieve some sort of publication the 
investigators must demonstrate some sort of feasibility that their gold nanoparticle-based 
technology can work for a particular application. Although many of these publications are 
significant contributions, most of the work is devoted to scientific discovery and not clinical 
translation. Unfortunately, this leaves a gap between academic development and clinical 
product development. Once feasibility in a technology has been established, financial funding is 
the main determinant of clinical translation. As shown in Figure 1, public grants can only take a 
technology so far, and eventually will need to rely on private funding.  
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Figure 1.  Cash flow diagram adapted from [1]. The cash flow as a function of development 
stage (time) with typical funding sources at various stages. SBIR, Small Business Innovative 
Research; STTR, Small Business Technology Transfer.  
 
 The finances involved with any clinical product development are very substantial and 
generally investors weigh the finances with how long to receive FDA approval and return on 
investment. Gold nanoparticle technologies developed based on scientific discovery generally 
have a lot of innovative aspects to them, which equals additional regulatory oversight and a 
longer path to clinic. Both public (e.g., business grants) and private investors are generally less 
enthusiastic about these type of technologies as they can often be considered too high risk 
investments. 
Assuming that the technology has the correct mix of innovation while being simple 
enough to have a relatively quick path to the clinic, there are a variety of different funding 
sources, as shown in Figure 1. Because many technologies start in academic laboratories, the 
initial funding source is government grants. A technology can be backed by public funding for a 
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significant portion of the clinical product development. There is precedent that public funding 
has taken technologies as far as early clinical trials, however most technologies must make the 
jump from public to private funding sometime before Good Manufacturing Practices (GMP) 
production is required.  
Gold nanoparticles are not trivial to manufacture, requiring high purity ingredients and 
reactors. Further complicating the manufacture is that gold nanoparticle formation is a 
stochastic process and requires extremely expensive characterization equipment (e.g. 
transmission electron microscopy). If a biomolecular targeting group is involved (e.g. antibody, 
peptide, nucleic acid, affibody, or anything that could cause an immunologic response) then the 
required quality controls (QCs) and quality assurances (QAs) are even more complex. Once the 
quality systems are established and the gold nanoparticle manufacture is fully integrated into 
current GMP, then the next step will be extensive toxicity studies. To be cleared by the FDA to 
perform a clinical trial, these toxicity studies must be performed under Good Laboratory 
Practices (GLP). Maintaining a GLP facility is extremely expensive and therefore most 
technologies outsource these studies to a GLP-certified contract research organization (CRO). 
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) has outlined most of the guidelines for toxicity studies, and depending on the 
method of action of the gold nanoparticle, will determine the number of animal species and 
testing burden required. For simple gold nanoparticle interventions, ones with no biologic and 
only a single low dose, the GLP toxicity study costs can be less than $100,000. However, 
complex interventions that include a biologic, or a known toxic agent, and multiple dosing could 
escalate costs to over $10,000,000. 
 Investments of this level are not readily available for a technology class that has not 
been approved by the FDA. Therefore, many of the technologies entering clinical trials are 
generally considered as ‘high-risk high-reward’. Due to the nature of these technologies, clinical 
testing will likely proceed for quite some time until approval can be obtained. Once one gold 
nanoparticle-based technology is approved, then some of the required GLP toxicity studies and 
clinical trials may be bypassed. This will greatly reduce commercialization times and costs for 
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subsequent products seeking FDA clearance, encouraging more private investments and driving 
more gold nanoparticle-based technologies to the clinic. 
 
Advances in science and technology to meet challenges 
 The major concerns with the FDA is safety and effectiveness, and until recently none of 
the gold nanoparticle technologies have moved past Phase 1 in-human safety studies. Although 
this may not necessarily be the case of these technologies, some gold nanoparticles are known 
to suffer from poor clearance from the body.[2] It has been shown that gold largely 
accumulates in the mononuclear phagocyte system (MPS) (also known as the 
reticuloendothelial system) because the body cannot break-down gold and most technologies 
require gold nanoparticles too large to be cleared by the kidneys. Therefore, if the technology 
uses gold as a drug delivery vehicle, there are questions as to why gold should be chosen as 
opposed to other existing technologies. If the technology uses gold as an energy converter for 
therapy (e.g., photothermal therapy or radiation therapy) or imaging contrast (e.g., 
photoacoustic/optoacoustic imaging), then questions about dosage and biodistribution are at 
the forefront. Therefore, current systemically delivery applications of gold nanoparticles are 
limited to high-morbidity indications. 
Advances in delivery and clearance will probably have the most profound influence on 
the future of clinical translation of gold nanoparticles. Effective delivery, either by improving 
bioavailability for lower effective doses or molecular targeting strategies, could have a 
profound effect on the potential safety profile of gold nanoparticles. If the clearance problem is 
solved, then long-term accumulation concerns will be reduced and could open gold 
nanoparticle applications for low-morbidity interventions. 
 
Concluding remarks 
The clinical presence of gold nanoparticle is on the rise, with at least eight new clinical 
trials listed in the past three years. Despite the financial burden to get a technology through 
feasibility and preclinical testing just to get a shot of testing into humans, several 
companies/groups have demonstrated that it can happen and is happening at an increasing 
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rate. The presence of the Phase 2 trials is really encouraging for the gold nanoparticle field, 
since it signifies the first time that gold nanoparticles have moved past Phase 1 safety studies. 
Hopefully these pioneering clinical trials pave the way for many more gold nanoparticle-based 
technologies, ushering in entirely new classes of diagnostics and therapeutics. 
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Next-Generation Metallic Nanoparticles for 
Cancer Radiation Therapy 
Bijay Singh, Srinivas Sridhar 
Department of Physics, Northeastern University, Boston MA 02115 
 
 
Status 
High Z elements (heavy metals) behave as potent radiosensitizers because they can 
produce a cascade of Auger electrons when ionized by X-ray irradiation [1]. In fact, the 
increment of resonant energies in heavy metals after irradiation is adequately high to 
ensure significant penetration in body tissue [2]. Laboratory experiments, using heavy 
metals injected into tumors and then irradiated with high-energy X-rays, have exhibited 
considerable reduction in tumor sizes [3]. Most importantly, the in situ deposition of 
radiation energy, followed by secondary photon and electron emission, will be confined 
at the irradiated tumor site. Due to these benefits, various formulations made of heavy 
metals have been conceived and developed to improve the radiation dose 
enhancement for cancer treatments. 
 
Current and future challenges 
Among high Z elements, gold (Z=79) has been the prime choice for radiation therapy 
due to its biocompatibility and low toxicity. Although the earliest studies with bulk or 
larger particles of gold to enhance radiation dose were successful in vitro, the larger 
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gold particles failed to show their effectiveness in vivo. Alternatively, gold nanoparticles 
(AuNPs) with diameter (1-5 nm) were produced and intravenously injected to enhance 
the accumulation of these ultrasmall particles in tumor tissues. As a consequence, when 
the tumor was irradiated, the 1-year survival was 86% compared to 20% with radiation 
alone and 0% with gold alone [3]. Following the successful result, innumerable studies 
have focused on the optimization of composition and size of AuNPs, uptake of 
nanoparticles into cells, and the dose of applied radiation. 
A major problem of AuNPs is their short circulation in the blood stream after injection, 
requiring immediate irradiation. But, a high dose of AuNPs, required for satisfactory 
treatment of tumors, is impractical for human use, partly due to toxicity concerns. To 
use the AuNPs for clinical applications, the size, surface chemistry and targeting ability 
of AuNPs could be tuned for longer circulation time and enhanced accumulation in 
specific tumors. A vast array of chemical agents (cysteamine, glucose, choline, citrate, 
folic acid), biomolecules (nucleotides, peptides, antibodies) and polymers (synthetic, 
natural) are available to conjugate to AuNPs to facilitate the higher uptake of particles in 
tumors. Although targeting agents may ameliorate the delivery of AuNPs to tumor sites, 
it is not fully understood whether these modified particles really assist radiation for 
tumor therapy. Again, optimization of AuNPs with optimum density of targeting agents 
and delivery routes (intravenous, intratumoral) is necessary prior to clinical translation. 
To date, only a few clinical trials (<10) of AuNPs are currently underway for cancer 
treatment [4] [5] [6]. 
 
Advances in science and technology to meet challenges 
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In pursuit of alternatives to AuNPs, other high Z elements such as bismuth (Z=83), 
platinum (Z=78) and gadolinium (Z=64) are currently being investigated to prepare the 
formulations for radiation therapy. Under similar conditions of size and concentration of 
particles, bismuth provides higher dose enhancements than gold while platinum shows 
equivalent efficacy to gold [7]. Particularly, bismuth oxide nanoparticles (BiNPs) are 
verified as efficient dose enhancing agents demonstrating their potential application in 
clinical radiotherapy [8]. Bismuth selenide nanoplates have shown significant radiation 
dose enhancement both in vitro and in vivo [9]. Of note, these nanoplates were 
selectively accumulated in tumor tissue after intraperitoneal injection into mice. The 
higher concentration of nanoplates not only enhanced the contrast of X-ray 
computerized tomography (CT) images but also led to damage on the tumor cells when 
exposed to radiation.  
A targeted radiotherapeutic agent was developed from bismuth nanosheets coated 
with chitosan and RGD peptide [10]. The nanosheets exhibit targeting ability to αvβ3 
integrin-overexpressing HeLa cells with higher radiosensitization efficiency. When the 
mice bearing HeLa tumors were irradiated after treatment with the nanosheets by 
intravenous or intratumoral injection, the tumor volume decreased significantly. 
Importantly, the nanosheets can be used for photoacoustic imaging and magnetic 
resonance (MR) imaging to study their targeting ability and therapeutic effects 
together. Thus, this study reveals an effective theranostic agent for next-generation 
cancer radiotherapy. In another study, functionalization of BiNPs with hyaluronic acid 
enhanced water solubility, biocompatibility and targeting ability to cancer cells 
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overexpressing CD44 receptors [11]. These particles offer great promise for target-
specific CT imaging and radiosensitization of tumors. 
Although nanoparticles of high Z elements are used as radiosensitizers to enhance 
radiation therapy, the non-degradable nature of the nanoparticles, that can cause long-
term toxicity when accumulated inside body, is a major bottleneck in translating 
nanoparticle radiosensitizers into clinical application for cancer treatment. To address 
the issue, a new formulation of folate and red blood cell membrane (F-RBC) combined 
BiNPs was developed, where folate targets tumor and cell membrane coating provides 
longer blood circulation time [12]. When F-RBC BiNPs were used to sensitize radiation 
for breast cancer treatment, there was significant tumor inhibition in mice resulting in 
improved survival ratios. Histological and in vivo bio-distribution analyzes revealed F-
RBC BiNPs were excreted after 15 days from the animal body with no evident damage 
or inflammatory response in major organs. 
Gadolinium (Z=64) is another alternative to gold which has been routinely used as a 
contrast agent in MR imaging. For instance, gadolinium oxide nanoparticles behave as 
efficient positive contrast agents for MR imaging and show radiosensitizing effects in 
gliosarcoma rat models [13]. In a new report, bovine serum albumin coated gadolinium 
nanoclusters were developed as multifunctional theranostics that could be used for 
CT or MR imaging and photothermal or radiation therapy of tumor treatment [14]. 
Moreover, the low toxicity and efficient renal clearance of these theranostics suggest 
their practical applications for cancer diagnoses and therapies. A new gadolinium 
nanoparticle agent, named AGuIX (Activation and Guidance of Irradiation by X-Ray), 
has recently been established as a potent radiosensitizer in cancer treatment. AGuIX 
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has high capacity of absorption of photons delivered by a radiotherapy beam which 
generates an enhanced local dose deposit. Accordingly, combining AGuIX with 
radiation therapy greatly enhanced tumor cell death, and improved the survival ratio of 
animals with multiple brain melanoma metastases [15]. Currently, the first phase I trial is 
going on to study the side effects and optimum dose of AGuIX when given together with 
whole brain radiation therapy in treating patients with multiple brain metastases [16]. 
Magnetic particles are another option to use in cancer radiation therapy in combination 
with hyperthermia. Hyperthermia is a treatment of cancer by exposing tumor tissues to 
high temperatures which can damage and kill cancer cells, usually with minimal harm to 
normal tissues. Hyperthermia may induce some cancer cells to be more sensitive to 
radiation or damage the cancer cells that radiation cannot kill. Iron oxide nanoparticles 
(FeNPs), due to their low toxicity and ability to emit heat energy when excited by 
magnetic fields, are generally used in hyperthermia. Additionally, FeNPs are used as 
contrast agents for MR imaging. Due to these benefits, several varieties of FeNPs have 
been produced for cancer therapy. Typically, dextran-coated FeNPs have shown to 
decrease tumor growth in a breast cancer model using hyperthermia and irradiation 
[17]. Most importantly, both intracranial and intratumoral hyperthermia using FeNPs 
combined with radiotherapy could be safely applied on patients with glioblastoma 
multiforme [18] [19]. A few studies have also focused on the radiosensitization 
properties of FeNPs. Irradiation on human prostate carcinoma cell line (DU145) with 
FeNPs (1 mg/ml) produced a dose enhancement factor of approximately 1.2 [20]. In 
another study, several tumor cells were irradiated in the presence of citrate- or malate-
coated FeNPs, where a drastically increased concentration of reactive oxygen species 
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in the tumor cells verified these nanoparticles as potent radiosensitizers for radiation 
cancer therapy [21]. 
Recently, Iodine nanoparticles (INPs) are developed for radiotherapy to overcome the 
drawbacks of AuNPs in clinical translation [22]. The major drawbacks of AuNPs are due 
to cost, skin discoloration and poor body clearance. In contrast, INPs have unique 
characteristics; they are almost colorless, non-toxic, and cost-effective in manufacturing. 
Above all, INPs show higher body clearance from the liver (50% in 6 months) compared 
to AuNPs (9% in 6 months) [23]. Experimentally, INPs when combined with 
radiotherapy or chemotherapy extended the survival period of the treated groups [22]. In 
addition, INPs have compatible size (20 nm) for better tumor penetration compared to 
liposomes (>100 nm) [24], and they, being coated with PEG, have longer blood half-life 
(40 hours) for better tumor uptake. When injected through intravenous route, INPs 
strongly accumulates in tumors at high levels providing extended-time for high contrast 
vascular and tumor imaging [26]. 
 
Concluding remarks 
Although significant progress has been made in radiation therapy for cancer treatment 
using metallic nanoparticles, the inherent radioresistance and inaccuracy of localization 
of nanoparticles in tumors weaken the clinical implementation. Hence, the development 
of nanosized particles with versatile properties (biocompatibility, low toxicity and 
targeting efficacy) to use in imaging-guided radiation therapy has always been a top 
priority in biomedical research. Next generation metallic nanoparticles decorated with 
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biocompatible coating and functionalized with ligands specific to cancer cells will solve 
the current problems of imaging and therapy. 
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Theranostics Metallic Nanoparticles   
Udoka M. Ibeh, Wilfred Ngwa 
Brigham and Woman’s Hospital & Harvard Medical School, Boston, MA 
 
 
Status 
In recent years, the field of nanomedicine has experienced significant growth in research 
interest. The use of metallic nanoparticles (MNPs) has been especially notable due to both the 
number of scientific publications advancing the field and the scope of applications. 
Advancements in synthesis, conjugation, transport and distribution patterns of nanoparticles have 
allowed for their use in numerous biomedical applications. Coupling the diagnostic and 
therapeutic capabilities of these MNPs to form theranostic agents is an active area of research. 
The therapeutics research area seeks to increase nanoparticle targeting, treatment dose 
distribution, and multidrug delivery. Concurrently, the diagnostics area provides improved image 
quality and enhanced contrasts. Nanoparticle theranostics harnesses the multi-functionality of 
MNPs to allow for continuous diagnosis or assessment of patients before, during and after 
therapy to better understand and increase treatment efficacy. This would allow for the 
development of more tailored therapies, and  improvements in patient prognosis1,2. 
 
 
Figure 1: Metallic Nanoparticle designed for theranostic applications. 
 
The synthesis of nanoparticle theranostic agents can occur in several ways. Therapeutic 
nanoparticles can be conjugated with contrast agents such as radioisotopes or additional imaging 
contrast agents to induce additional diagnostic imaging functionalities. Conversely, imaging 
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nanoparticles can be conjugated with therapeutic agents such as drugs,  radio and 
photosensitizers,  and  therapeutic moieties to induce therapeutic functionalities3. Certain 
metallic nanoparticles have intrinsic theranostic (therapeutic and imaging contrast) capability 
(e.g. gadolinium or gold nanoparticles). Other nanoparticles may be hybrid nanoparticles—
composed of more than one metal. Such combination promises to be more effective as it can 
make use of the inherent positive characteristics of each metal making up its composition4. Much 
focus has been placed on refining nanoparticle synthesis as it is an important determinant of its 
functionality.  
Due to the inherently complex nature of biological systems, nanoparticles must be 
optimized to have specific and measurable mechanics. They must have large enough blood 
circulation half-lives to allow them to reach their targeting site. In their therapeutic applications, 
they must be able to efficiently deliver a specific dose of drugs to a localized region so as to 
decrease toxicities. Once delivered, they must be able to be rapidly and specifically accumulate 
within biological targets of interest in order to reduce collateral damage and to increase treatment 
specificity. In their diagnostic applications, they must be able to analyze and report the 
biological, biochemical and morphological characteristics of the tissue or disease of interest in an 
effective way. After performing their theranostic tasks, they must be effectively degraded into 
noncytotoxic byproducts or be cleared from the body quickly and effectively without inducing 
any toxicities3. 
 
Current and Future Challenges 
Most nanoparticles when used in solid tumors for imaging and drug delivery rely on the 
Enhanced Permeability and Retention (EPR) effect to localize within the tumor 
microenvironment. This EPR effect is induced by aberrant tumor vasculatures that are 
characteristic of most solid tumors5–7.  Unfortunately, it also leads to extensive difficulties when 
attempting to determine how to best optimize nanoparticles for specific targeting—as it becomes 
significantly difficult to determine environmental conditions and create predictable diffusion or 
transport mechanisms5,8. Engineering nanoparticles that have dynamic active targeting 
capabilities is an important field of interest. 
A significant hurdle in the use of nanoparticle theranostics in clinical settings is due to an 
inability to generate theranostic agents capable of meeting all the above-mentioned nanoparticle 
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optimization criteria. In the current state of nanoparticle synthesis, strides in one direction often 
require that compromise be made in other directions. For example, increasing blood circulation 
half-life often leads to increased toxicity. Conversely, conjugating nanoparticles with tumor-
specific ligands for increased binding often leads to decreased blood circulation half-life. 
Discerning methods to simultaneously achieve these criteria without sacrificing any is an active 
area of research1,3 
Several parameters that must be optimized for the use of these nanoparticles in everyday 
clinical practice includes: optimizing nanoparticle materials based on their intended goals, 
increasing the efficiency of ligand conjugations, decreasing the cost of nanoparticle synthesis 
and conjugation, and development of methods that allow for consistent reproducible nanoparticle 
synthesis such that their size, density, and material composition remains homogenous. 
Furthermore, nanoparticles must be designed to be able to avoid innate immune recognition, 
though they could also be tailored to enhance immunotherapy.  
 
Advances in science and technology to meet challenges  
 Metallic nanoparticles have intrinsic physicochemical and biocompatible properties that 
make them strong candidates for theranostic applications. Gold nanoparticles have been shown 
to be relatively noncytotoxic, to increase the therapeutic ratio of radiotherapy, and to improve 
local imaging9–13. Recent advancements in this space have led to the development of metallic 
nanoparticle conjugates capable of selectively binding tumor-specific ligands. One such example 
utilizes the angiogenic markers characteristic of many tumors. A second mechanism is the 
generation of folate-conjugated porphysomes based nanoparticles which utilize the fact that the 
folate receptor, a glycosylphosphatidylinositol-linked membrane protein, is highly expressed in 
many tumors and has a high affinity for folic acid14–17. 
Because nanoparticle theranostics is a combination of the diagnostic and therapeutic 
fields, independent progress in any of these two fields, theoretically can advance theranostics; 
one type can simply be conjugated with the characteristics of the other to form theranostic 
capabilities6. The Food and Drug Administration (FDA) has successfully accepted more than 35 
nanoparticles for therapeutic and image diagnostic use in clinical trials2,3. These nanoparticles 
can be employed as platforms to incorporate theranostic agents and thus be able to reach clinical 
trials which will allow for expedited approval for clinical trials.     
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Substantial effort has gone toward formulating mechanisms that increase the circulatory 
half-life of theranostic nanoparticles. By coating nanoparticle theranostics with cellular 
membrane of leukocytes and red blood cells, their susceptibility to immune recognition is 
considerably minimized18. These nanoparticles can also be synthesized to show active targeting 
of select tumors by conjugating multiple targeting ligands to the nanoparticle. Furthermore, one 
active area of research looks to map out the diffusion and accumulation of varying nanoparticle 
sizes on breaking through the vasculature epithelium to accumulate in tumor 
microenvironments8. 
 
 
Conclusion 
 Nanoparticle Theranostics using MNPs has become a very active field of research and 
promises to both enhance therapeutic delivery and retention of chemotherapeutics, 
photosensitizing and radiosensitizing agents, as well as improving imaging quality. Although 
only few nanoparticle platforms have reached clinical trials, the significant amount of interest 
and research activity in this space promises to quickly change that. The use of nanoparticles as 
theranostic agents will help enhance personalized disease therapy by enabling continuous and 
concomitant diagnosis and treatment.  Developing agents capable of long blood circulation, 
specific therapeutic dose delivery, decreased toxicity and an ability to specifically accumulate 
within a target region are all avenues of ongoing studies. 
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Metallic Nanoparticles for Enhancing 
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Status 
The treatment of cancer has been transformed by immunotherapy, which now 
represents a fourth pillar of modern cancer therapy with surgery, radiotherapy, and 
chemotherapy. For many cancers, immunotherapy is combined with standard therapies 
to improve locoregional tumor control and overall survival rates. However, many 
patients receiving immunotherapy fail to achieve long-term, durable responses. A recent 
clinical trial for head and neck cancer showed that 20% of patients achieved a 
radiographic treatment response to immunotherapy, while responses in melanoma, 
renal cell carcinoma, and lung cancer range from 20–25%.[1,2] Innovative strategies 
are needed to bolster immunotherapy responses.   
In certain clinical contexts, radiotherapy can act synergistically with immunotherapy. 
Radiotherapy triggers immunological cell death (ICD), release of tumor-associated 
antigens (TAAs), and radiation-induced neoantigens. Modulation of the tumor 
microenvironment (TME) following radiotherapy elicits immunostimulatory effects such 
as cytotoxic T-cell infiltration. While immunosuppressive factors in the TME offset some 
of the salutary effects of radiation, coupling radiotherapy with immunotherapy can tip the 
scale towards more immunogenic effects.[3] Recent data from patients treated with 
radiotherapy combined with immunotherapy suggest that this approach may have 
clinical utility.[4–6] 
An area of interest for radiotherapy and immunotherapy synergy is the abscopal effect. 
Proponents posit that the local effects of radiotherapy can activate systemic anti-tumor 
immunity and cause regression of distant, non-irradiated tumors. While the abscopal 
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effect has been reported in preclinical models and case reports, approaches to 
reproducibly elicit abscopal responses in patients remain undefined.   
Given the role of metallic nanoparticles (MNPs) as radiotherapy enhancers, there is now 
interest in determining whether MNPs may likewise enhance immunotherapy. The 
delivery of immunostimulatory agents into the TME may also be facilitated by 
nanoparticle carriers. Through their dual roles as radiotherapy enhancers and carriers of 
immunostimulatory agents, nanomedicines could have an increasing role in the next 
generation of immunotherapy-based treatments.  
 
Current and Future Challenges 
Initial case reports of the abscopal effect generated significant interest and have led to 
hundreds of preclinical studies and clinical trials combining radiotherapy and 
immunotherapy.[7] However, it remains uncertain how to reproducibly elicit abscopal 
effects in patients. For nanomedicine to impact immuno-oncology, at least three 
questions must be addressed: (1) Can nanomaterials amplify radiotherapy-induced ICD 
and release of TAAs? (2) Can nanomaterials modulate the immunosuppressive TME? 
(3) Can nanomaterials-based treatment strategies limit immune-related systemic 
toxicities?  
Preclinical data suggest that the radiation dose per fraction is correlated with activation 
of anti-tumor immunity. Doses greater than 8 Gy per fraction increased anti-tumor 
immunity via the cGAS/STING pathway as measured by interferon-beta (IFN-b) 
expression, activated dendritic cells (DCs), and infiltrating cytotoxic T-cells. Doses 
above 20 Gy per fraction diminished anti-tumor immunity via activation of the DNAse 
Trex1, suggesting an optimal window in which radiotherapy bolsters anti-tumor 
immunity.[8] A recent study of ablative radiotherapy combined with CTLA-4 immune 
checkpoint inhibitors reported increased T-cell diversity and cytotoxic T-cell expansion 
and decreased immunosuppressive regulatory T-cells.[9] MNPs including gold and 
hafnium oxide nanoparticles are well-established as radiosensitizers via the increased 
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production of secondary electrons.[10] Emerging data suggest that MNPs may lead to 
increased anti-tumor immunity by amplifying the biological effects of radiotherapy.   
The interactions between nanomaterials and the immune system are multifaceted. 
Nanomaterials bolster immune activity by several mechanisms, including delivering 
immunoadjuvants to stimulate DC maturation, increasing TAA release, and modifying 
the TME to promote T-cell infiltration.[11] However, the innate and adaptive immune 
systems have evolved mechanisms to recognize and remove ‘non-self’ entities including 
nanomaterials. Circulating and tumor-resident macrophages can efficiently phagocytose 
nanomaterials to limit therapeutic benefit. The complex give-and-take between 
nanomaterials and the immune system presents multiple opportunities for improvement. 
For example, coating nanoparticles with CD47, a protein which evades phagocytosis, 
leads to reduced nanoparticle clearance rates.[12]  
Delivery of therapies and circulating cells into tumors is limited by transport barriers 
including blood flow, extravasation, and interstitial diffusion. Radiotherapy may promote 
anti-tumor immunity by modifying these physiologic transport barriers.[13,14] A 
comprehensive understanding is required at the molecular, cellular, and tissue levels to 
delineate how MNPs dynamically modify the TME and the resulting biological response, 
including infiltration and efflux of immune cells. The extension from these efforts would 
focus on developing nanomaterials that modify the TME to optimize activation of anti-
tumor immune pathways.   
An important consideration when combining radiotherapy and immunotherapy is the 
potential for immune-related toxicity affecting multiple organ systems. While studies 
have shown combined radiotherapy and immunotherapy to be well-tolerated, others 
have reported increased toxicity rates. [15] Many nanomaterial-based strategies have 
focused on improving therapeutic efficacy, but there may be beneficial opportunities for 
nanomaterials to reduce immune-related systemic toxicity. 
 
Advances in science and technology to meet challenges 
Increasing immunological cell death with nanomaterials 
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MNPs generate secondary electrons to amplify the radiation dose within tumors. Gold 
nanoparticles are established as radiotherapy enhancers via increased secondary 
electron production and reactive oxygen species (ROS) formation.[10] Investigators 
have established that gold nanoparticles can serve as radiosensitizers for megavoltage 
(MV) energies commonly used in the clinic.[16] Future work will clarify whether gold 
nanoparticles and radiotherapy can modulate anti-tumor immunity. Hafnium oxide 
nanoparticles are currently in clinical trials for head and neck cancer, soft tissue 
sarcoma, prostate cancer, and liver cancer. Initial data suggest that hafnium oxide 
nanoparticles combined with radiotherapy may increase ICD, T-cell infiltration, 
activation of adaptive immunity, and cytokine signaling compared to radiotherapy 
alone.[17] While intriguing, more data is needed through prospective clinical trials to 
determine the immunomodulatory properties of hafnium oxide nanoparticles. Additional 
nanomaterials including gadolinium, platinum, and cerium oxide have been explored as 
radiotherapy enhancers.[18] Because of their shared mechanisms for enhancing 
radiotherapy, approaches combining MNPs with chemical oxygen mimetics such as 
nimorazole or misonidazole may be beneficial for local control of treatment-refractory 
hypoxic tumors.  
Immune-Nanomaterial interactions in the tumor microenvironment 
Nanomaterials designed to modulate the TME are engineered to have pharmacokinetic 
(PK) and biodistribution properties that permit accumulation in the TME. Numerous 
studies have found that for particles of similar charge and hydrophilicity, the principal 
systemic clearance mechanisms are renal and hepatobiliary excretion for smaller and 
larger particles, respectively.[19] An additional factor is the interaction of nanomaterials 
with circulating and tissue-resident macrophages. CD47-coated nanoparticles showed 
reduced rates of phagocytosis by activated M1 macrophages, demonstrating that 
surface modifications of nanomaterials can alter the interaction between nanomaterials 
and immune cells.[12] Incorporating immunoadjuvants into nanomaterials represents a 
promising approach to modify the TME. While radiotherapy can be transiently 
immunostimulatory, opposing immunosuppressive factors in the TME may negate this 
effect.[3] Nanomaterials localized to the TME that deliver a sustained release of 
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immunostimulatory molecules may be beneficial for activating anti-tumor immunity. 
Research aimed at deciphering the multiscale interactions between nanomaterials, the 
TME, and immune system will be informative toward these efforts. Advanced imaging 
techniques such as intravital microscopy, genetically-engineered mouse models 
(GEMMs), and fluorescently-labeled cells and nanomaterials may be combined in 
innovative ways to reveal dynamic interactions in tumors.  
Nanomaterials to reduce toxicity of radiotherapy and immunotherapy 
Using nanomaterials to deliver immunotherapy to the TME and surrounding lymphatics 
may offer an approach for minimizing toxicities of systemic immunotherapy. A recent 
study investigated this approach in a preclinical model in which tumors received 
radiotherapy with intratumorally-administered anti-CD40 antibody in an emulsified 
formulation that permitted sustained local release.[20] Maximizing the intratumoral 
concentration of nanomaterials to reduce systemic toxicity can be achieved by at least 
several mechanisms. Direct intratumoral injection of nanomaterials is being explored in 
preclinical and clinical studies. Delivery of molecules using nanoparticle carriers can 
also increase local concentrations of immunotherapies while reducing systemic 
toxicities. Efforts to target nanomaterials would include cataloging secreted proteins in 
the TME and those upregulated following radiotherapy to identify potential targeting 
ligands. Inter- and intra-tumor variability are relevant factors, as tumor sequencing has 
revealed considerable genetic and molecular heterogeneity between tumors.  
 
Concluding Remarks 
While immunotherapy has transformed modern oncology, many patients fail to achieve 
long-term, durable responses. Efforts are underway to bolster responses by combining 
radiotherapy with immunotherapy. Given the role of MNPs as radiotherapy enhancers, it 
follows that combinations of MNPs, radiotherapy, and immunotherapy may improve 
local and distant tumor control. We have highlighted several challenges in this emerging 
field. Can MNPs increase ICD following radiotherapy? Can MNPs evade macrophages 
and other clearance mechanisms in vivo? Can MNPs reduce the toxicity of systemic 
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immunotherapy? The multiscale complexity of this work requires collaborations between 
biologists, chemists, engineers, and clinicians. Based on early results, there is cause for 
cautious optimism that nanomaterials-based solutions will maximize immunotherapy 
and radiotherapy responses in cancer patients.   
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Concluding Remarks: 
Jan Schuemann1, and Sunil Krishnan2 
1 Department of Radiation Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, 
MA 02114, USA 
2 Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 
 
 
This special collection of mini-articles on metal nanoparticles in radiation therapy provides a series of 
commentaries on the state-of-the-science and where the field in headed in the future, both in the 
laboratory and in the clinic. Drawing on the expertise of a non-complete selection of thought leaders in 
the field, this collection charts out a roadmap for future research activities. Each commentary outlines 
lessons learned on the path to where the field is today, highlights perceived challenges as the field 
advances towards the future, and finally discusses scientific and technological advances that might help 
overcome hurdles in the future. Although this is a compilation of several commentaries, the terseness of 
each commentary (mandated by the journal and us) makes for easy reading of multiple viewpoints from 
multiple perspectives and disciplines, all coalesced under one umbrella. We believe such a compilation 
of opinion pieces is especially interesting for an uninitiated reader who is looking for a high-level 
overview in broad brushstrokes. More in-depth information is readily available in articles referenced by 
the authors, many of which are co-authored by the same experts who wrote the commentary. For more 
advanced readers, these articles offer a summary of current challenges and an outlook of where we 
envision the field is headed.  
 
A theme that emerges across all commentaries is that the science of fabricating, characterizing, 
decorating, imaging, and modeling of metal nanoparticles is mature and highly sophisticated. 
Nanoparticles are now used for a large variety of applications, most notably for functional imaging that 
has already advanced into the clinic. In the theranostic or radiation dose enhancing realm, the 
understanding of the underlying physical, chemical and biological consequences of interactions between 
these nanoparticles and ionizing radiation is evolving rapidly. Preclinical data across research teams are 
exciting and consistent in their ability to enhance radiation therapy effectiveness via physical and 
biological radiation sensitization. Against this background of palpable excitement are broad efforts to 
translate these technological advances to clinical reality after addressing safety, biocompatibility and 
scale-up issues. These clinical adoption strategies may span a variety of metallic nanoparticle constructs, 
a spectrum of targets within the tumor microenvironment, and combinations with other therapies 
including chemotherapy or immunotherapy. The enormous progress made in our understanding of 
fundamental nanoparticle-radiation interactions is especially meaningful because it has required the 
concerted efforts of scientists in disparate disciplines working individually or, more often, in unison to 
achieve these goals. While challenging questions remain regarding the best way to synergize 
nanoparticle use with radiation therapy without collateral toxicity, the overall therapeutic approach 
remains highly promising. As can be seen from the articles, all of the authors share the vision of 
advancing the outcome of radiation therapy using various constructs of nanoparticles by providing 
better imaging or therapeutic effects or a combination of both. Widespread clinical translation is long 
overdue. We hope this collection of research reflections and anticipated future directions will play a 
small role in making our vision of routine clinical use of metallic nanoparticles to enhance therapy a 
reality.  
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